Hypoglycemia (2024)

by Rok Petrovčič

 

You Have A New Patient!

A 75-year-old woman was brought to the emergency department by her relatives for “not being her usual self” for the past day. Her relatives reported that the patient had not eaten much of her usual breakfast, as she was not feeling well. She was on insulin therapy for diabetes but was otherwise healthy, with no reported allergies. At triage, she appeared confused and disoriented. Her vital signs were as follows: HR 95/min, RR 18/min, BP 141/85 mmHg, T 37.7°C, and SpO₂ 99% on room air. 

The image was produced by using ideogram 2.0

Given her past medical history, a capillary blood glucose test was performed at triage, which revealed a reading of 2.6 mmol/L (47 mg/dL). She was laid down and brought to an examination room on a stretcher.

What Do You Need To Know?

Importance

Hypoglycemia is a common medical emergency that is easily treatable but can be life-threatening if not addressed promptly. It is a frequent condition in patients with diabetes. Hypoglycemia can cause a variety of symptoms, including confusion, loss of consciousness, seizures, and even coma. These symptoms can be mistaken for other conditions, so it is important to recognize the signs of hypoglycemia and provide prompt treatment. Hypoglycemia can often be treated with oral glucose, but severe cases may require intravenous administration of glucose or other medications. Knowledge of appropriate treatments for hypoglycemia is crucial to prevent serious complications. Hypoglycemia may also occur in patients with other conditions, such as liver failure or sepsis. In these cases, it is also important to address the underlying condition [1].

Epidemiology

The epidemiology and incidence of hypoglycemia are difficult to study, as many patients experiencing hypoglycemic symptoms recognize and treat them without visiting the emergency department (ED). Hypoglycemia is more common in patients with type 1 diabetes and less common in those with type 2 diabetes, due to therapies that less frequently induce hypoglycemia. In the United States, hypoglycemic events contribute to 100,000 emergency department visits annually, costing $120 million [2].

Pathophysiology

Glucose is the main source of energy, and its lack causes the release of glucagon, catecholamines, and growth hormone, leading to adrenergic symptoms. Hypoglycemia can be iatrogenic or secondary to an underlying disease process. Common causes of hypoglycemia in diabetic patients include medication (increased medication intake or decreased oral intake), infection, and worsening kidney function. In non-diabetic patients, common causes include infection, liver disease, and malignancy. Other causes in both groups of patients include Addison disease, adrenal crisis, cardiogenic shock, hypopituitarism (panhypopituitarism), inadequate intake of food, insulinoma, poisoning, stress, and suicide attempts involving anti-diabetic agents [1,3].

Medical History

Taking a thorough history in a hypoglycemic patient is critical for determining the etiology and guiding appropriate management. Below are key elements to address during history-taking:

1. Dietary History

Ask the patient about the timing, content, and size of their last meal. Skipping meals or consuming inadequate carbohydrates can precipitate hypoglycemia, particularly in individuals on glucose-lowering therapies. Recent fasting, changes in eating patterns, or prolonged periods without food (e.g., due to illness or dietary restrictions) should also be noted.

2. Physical Activity

Inquire about recent exercise or physical exertion. Increased physical activity, particularly without appropriate adjustments in food intake or medication, can lead to hypoglycemia. This is especially relevant for individuals on insulin or insulin secretagogues such as sulfonylureas [3].

3. Alcohol Use

Assess the patient’s alcohol consumption, including the amount and timing. Alcohol impairs gluconeogenesis in the liver and can precipitate hypoglycemia, particularly in individuals who have not eaten or who are on glucose-lowering medications.

4. Medication History

For patients with diabetes, a detailed review of their diabetic medication regimen is essential. Obtain information about the specific drugs used (e.g., insulins—categorized as rapid-, short-, intermediate-, or long-acting—or sulfonylureas), doses, and timing of administration. Missing meals or using incorrect dosages are common contributors to hypoglycemia in this population [4]. Additionally, check for the use of other medications that may potentiate hypoglycemia, such as beta-blockers or quinolone antibiotics.

5. Symptoms of Infection or Ischemia

Infections and ischemic conditions can exacerbate hypoglycemia by increasing metabolic demand or altering medication effects. Ask about recent fever, chills, cough, dysuria, chest pain, or other signs and symptoms that could indicate an underlying infection or ischemic event.

6. Drug Overdose or Intentional Harm

In cases of suspected hypoglycemia secondary to drug overdose, particularly with oral hypoglycemic agents like sulfonylureas, inquire about potential intentional overdoses or suicidal ideation. A suicide risk assessment must be conducted in these situations, as hypoglycemia from overdose can be life-threatening [3,4].

7. Family or Social History

If the patient is unable to provide a history, gather collateral information from family members, caregivers, or emergency medical personnel. This can help identify risk factors, such as undiagnosed diabetes or recent changes in behavior or treatment.

Physical Examination

A thorough physical examination is essential for evaluating a hypoglycemic patient and identifying the severity and potential underlying causes of their condition.

1. Initial Assessment

In any patient presenting with coma, altered behavior, or neurological symptoms, hypoglycemia must be considered and excluded early. Immediate bedside glucose measurement is critical to avoid delays in diagnosis and treatment. Early recognition and intervention can prevent irreversible neurological damage.

2. Signs of Neuroglycopenia

Neuroglycopenic symptoms arise from insufficient glucose supply to the central nervous system (CNS). Carefully assess for:

  • Level of Consciousness: Evaluate for confusion, lethargy, or unresponsiveness, which may range from mild cognitive impairment to profound coma. The Glasgow Coma Scale (GCS) can quantify the severity of neurological dysfunction.
  • Focal Neurological Signs: Perform a focused neurological examination for signs such as hemiparesis or cranial nerve deficits, which may mimic stroke and complicate diagnosis. The resolution of these signs with glucose administration supports hypoglycemia as the cause.
  • Seizure Activity: Look for evidence of tonic-clonic movements or postictal states, as seizures may be caused by severe hypoglycemia.
  • Ophthalmological Signs: Check for blurred vision or nystagmus, which may indicate neuroglycopenic involvement.

3. Adrenergic Signs

Adrenergic symptoms are the body’s compensatory response to hypoglycemia, mediated by catecholamine release. Key findings include:

  • Vital Signs: Look for tachycardia and tachypnea, which are nonspecific but often accompany adrenergic activation.
  • Skin Examination: Diaphoresis (profuse sweating) is a hallmark adrenergic response and can serve as a clinical clue.
  • Behavioral Symptoms: Assess for signs of agitation, restlessness, or pronounced anxiety, which may be linked to adrenergic stimulation.

The presence of adrenergic symptoms suggests an intact counter-regulatory response, whereas their absence in severe hypoglycemia may indicate an impaired sympathetic nervous system (e.g., in longstanding diabetes with autonomic neuropathy).

4. Whipple’s Triad

Whipple’s triad is critical for diagnosing hypoglycemia and should be confirmed whenever possible [3,4]:

  • Symptoms Consistent with Hypoglycemia: Correlate the findings of neuroglycopenic and adrenergic symptoms.
  • Low Blood Glucose Levels: Document with point-of-care testing or laboratory confirmation.
  • Resolution of Symptoms with Glucose Administration: Reassess the patient after treatment with glucose (e.g., oral glucose or IV dextrose). The resolution of symptoms reinforces the diagnosis.

5. Signs of Underlying Causes

Examine for evidence of potential precipitating conditions:

  • Infection: Check for fever, localized tenderness (e.g., chest, abdomen, or urinary tract), or signs of sepsis, as infections increase metabolic demand and can precipitate hypoglycemia.
  • Malnutrition: Assess for signs of cachexia or dehydration, which may indicate fasting or poor nutritional intake.
  • Drug Overdose: Look for clues such as medication vials, needle marks, or altered mental status in cases of suspected overdose with insulin or sulfonylureas.

6. Secondary Causes

Inquire about and examine for:

  • Adrenal Insufficiency: Hypotension, hyperpigmentation, and unexplained fatigue may point to Addison’s disease or secondary adrenal insufficiency.
  • Hypopituitarism: Look for evidence of chronic deficiencies such as hypotension, hypoglycemia, and bradycardia.

7. Systematic Re-Evaluation

The examination should be repeated after glucose administration to assess symptom resolution and identify any residual neurological deficits. Persistent focal findings or altered mental status post-treatment may indicate concurrent pathology, such as stroke or seizure disorder.

Alternative Diagnoses

If neurologic or behavioral symptoms persist after treatment with glucose, evaluate for concurrent causes of altered mental status using the mnemonic “TIPS AEIOU” [5]. A CT brain scan may be warranted.

  • A – Alcohol
  • E – Endocrine/Electrolyte/Epilepsy
  • I – Insulin
  • O – Overdose/Opioids/Oxygen
  • U – Uremia
  • T – Toxicologic/Trauma
  • I – Infection
  • P – Psychiatric/Poisoning
  • S – Stroke/Shock
ALTERED MENTAL STATUS

Acing Diagnostic Testing

A comprehensive diagnostic workup is crucial for identifying and addressing the cause of hypoglycemia while initiating timely treatment. 

1. Bedside Tests

Rapid bedside testing is the cornerstone for the initial evaluation of hypoglycemia:

  • Blood Glucose Measurement:
    Venous or capillary blood glucose should be checked immediately using a glucose oxidase strip. A glucose level <3.0 mmol/L confirms hypoglycemia. However, it is critical to remember that the severity of symptoms, rather than the absolute glucose value, determines clinical significance [3].
  • Point-of-Care Testing (POCT):
    Concurrent bedside tests such as arterial blood gas (ABG) analysis can provide information about acid-base status and potential coexisting conditions like sepsis or metabolic acidosis.

2. Laboratory Tests

Further laboratory investigations should be guided by the clinical presentation and differential diagnosis:

  • Formal Glucose Measurement:
    If hypoglycemia is detected on a bedside glucose test, a venous blood sample should be sent to the laboratory for a formal plasma glucose level. Importantly, treatment must not be delayed while awaiting these results.
  • Serum Insulin and C-Peptide:
    These are particularly useful when hypoglycemia secondary to endogenous hyperinsulinism or insulin overdose is suspected.
    • High Insulin and High C-Peptide: Suggest endogenous insulin production, as seen in insulinomas or sulfonylurea ingestion.
    • High Insulin and Low C-Peptide: Consistent with exogenous insulin administration [3].
  • Cortisol Levels:
    A low cortisol level may indicate adrenal insufficiency as a potential cause of recurrent hypoglycemia.
  • Glucagon Levels:
    Although not routinely assessed, glucagon levels can provide insights into counter-regulatory hormone responses during hypoglycemia.
  • Infection Markers:
    Full blood count, inflammatory markers (e.g., CRP, procalcitonin), and blood cultures should be obtained to investigate underlying sepsis or infection.
  • Toxicology Screen:
    Consider when an overdose of oral hypoglycemic agents or other substances is suspected.

3. Imaging Studies

Imaging is not routinely required for all patients with hypoglycemia but should be considered when specific conditions are suspected:

  • Chest X-Ray (CXR):
    Indicated if a respiratory infection or pulmonary source of sepsis is suspected.
  • Electrocardiogram (ECG):
    Perform in patients with suspected ischemia or when adrenergic symptoms such as tachycardia or chest pain are present.
  • Neuroimaging (CT or MRI):
    Obtain if the patient has persistent neurological symptoms after glucose correction or if there are signs of head trauma, stroke, or other CNS pathology.
  • Abdominal Ultrasound or CT Abdomen:
    Consider in cases of suspected pancreatic pathology, such as insulinoma or pancreatitis.

Key Considerations

  • There is no universally defined blood glucose threshold for hypoglycemia, as symptom onset varies among patients. Individual factors, such as baseline glucose control and underlying comorbidities, influence symptomatology [6].
  • Diagnostic tests should be tailored based on the clinical scenario to exclude critical conditions like infection, ischemia, or medication overdose. While advanced studies such as serum insulin and C-peptide are valuable, these are rarely performed in the emergency department and are more relevant in specialized or outpatient settings [3].

Risk Stratification

Factors to consider when risk stratifying patients with hypoglycemia include [3,7]:

  • Severity of hypoglycemia: Mild hypoglycemia can be managed by the patient with oral glucose or food, while severe hypoglycemia may require intravenous glucose and hospitalization.

  • Frequency of hypoglycemic episodes: Frequent hypoglycemic episodes can increase the risk of developing hypoglycemia unawareness, which may lead to more severe episodes in the future.

  • Underlying medical conditions: Patients with diabetes who have comorbidities, such as renal insufficiency or liver disease, may be at increased risk for hypoglycemia.

  • Age and cognitive function: Elderly patients or those with cognitive impairment may be at higher risk for hypoglycemia due to difficulty recognizing symptoms and managing their blood glucose levels.

  • Lifestyle factors: Patients with poor nutrition or irregular eating patterns may be at increased risk for hypoglycemia.

Management

Patients with hypoglycemia should be placed in a monitored area. If the patient has decreased consciousness or is unconscious, the airway should be protected, but intubation should be avoided prior to the administration of glucose. The means of reversing hypoglycemia depend on the patient’s mental status, ability to cooperate with oral intake, availability of intravenous access, and medical and medication history.

If the patient is conscious and able to cooperate with oral intake, administration of food or liquid rich in simple carbohydrates (e.g., a sugary drink, sugar, candies, or glucose tablets) is preferred. After this, the patient should receive a meal rich in complex carbohydrates, fat, and protein, such as a sandwich.

If the patient is unconscious or unable to cooperate with oral intake and intravenous access is available, administer 50 mL of IV dextrose 50% or 250 mL of 10% dextrose (equivalent to 25 g of dextrose) over a few minutes. A second dose can be administered if the patient’s mental status does not improve.

If intravenous access is not available, 1 mg of IM/SC glucagon can be administered. Glucagon takes longer to normalize mental status (approximately 7–10 minutes), and its effect tends to be short-lived. As glucagon raises blood glucose by mobilizing hepatic glycogen reserves, it is not effective in patients with depleted glycogen stores (e.g., liver failure or chronic alcoholism). Glucagon can also cause vomiting, which may be dangerous if the patient has an altered mental status and cannot protect their airway.

For patients with sulfonylurea overdose, commence therapy with IV dextrose until the patient can tolerate oral intake. If episodes of hypoglycemia recur despite glucose therapy, consider adding SC octreotide 50–100 micrograms. Note that octreotide should only be used for recurrent sulfonylurea-induced hypoglycemic episodes that persist despite glucose therapy [3,5].

Special Patient Groups

Pediatrics

Children are particularly vulnerable to the effects of hypoglycemia due to their higher metabolic rate and limited glycogen stores. Key points in management include:

  • Treatment Protocol:
    Administer 10% glucose at 5 mL/kg or 25% dextrose at 2.5 mL/kg intravenously for acute hypoglycemia. Avoid the use of 50% dextrose in this population, as its hypertonicity increases the risk of thrombophlebitis and local tissue injury [8].
  • Medication for Refractory Cases:
    For persistent hypoglycemia caused by hyperinsulinemia (e.g., from congenital hyperinsulinism or sulfonylurea overdose), octreotide is effective at a dosage of 1 μg/kg subcutaneously (maximum 50 μg). This medication inhibits insulin secretion and provides a targeted intervention [8].
  • Long-Term Considerations:
    Recurrent hypoglycemia in children warrants further investigation into metabolic or endocrine disorders, including inborn errors of metabolism, adrenal insufficiency, or insulinoma.

Pregnant Patients

Pregnant patients with diabetes, particularly those on insulin therapy, face a higher risk of hypoglycemia due to physiological changes during pregnancy, including increased insulin sensitivity in the first trimester.

  • Incidence:
    Up to 50% of pregnant patients with diabetes experience at least one episode of severe hypoglycemia during pregnancy, especially in the first trimester [4].
  • Management and Prevention:
    • Careful Insulin Titration: Frequent monitoring and adjustment of insulin doses are essential to balance optimal glycemic control with the prevention of hypoglycemia.
    • Dietary Counseling: Pregnant patients should be educated on consuming regular, balanced meals with adequate carbohydrate intake to prevent fasting hypoglycemia.
    • Monitoring: Emphasize regular blood glucose monitoring, as symptoms may be subtle or atypical.
  • Fetal Considerations: Prompt correction of maternal hypoglycemia is critical to prevent adverse effects on the fetus, including hypoxic injury from prolonged episodes.

Geriatrics

Older adults often experience atypical presentations of hypoglycemia, and their management is complicated by comorbidities, polypharmacy, and age-related physiological changes.

  • Atypical Presentations:
    Hypoglycemia in geriatric patients may lack typical adrenergic symptoms like tremors or sweating. Instead, symptoms such as confusion, lethargy, or falls may predominate, potentially delaying diagnosis.
  • Risk Factors:
    • Polypharmacy: Concurrent use of insulin, sulfonylureas, or other glucose-lowering agents increases hypoglycemia risk.
    • Renal Impairment: Reduced clearance of medications such as sulfonylureas or insulin exacerbates the risk of prolonged hypoglycemia.
    • Nutritional Deficits: Poor oral intake or prolonged fasting may contribute to hypoglycemia.

Intubated Patients

For intubated or sedated patients, hypoglycemia can be difficult to recognize because mental status changes are masked. In these cases, frequent glucose monitoring is essential [5].

When To Admit This Patient

Admission Criteria
Patients with hypoglycemia generally require admission to an observation unit or the general ward for evaluation and treatment of the underlying cause, as well as titration of diabetic medication.
Patients with unexplained or recurrent hypoglycemia should be admitted to a monitored area. Individuals taking sulfonylureas have an increased likelihood of experiencing recurrent and delayed-onset episodes of hypoglycemia. Consultation with a toxicologist and psychiatrist should be considered for patients who overdose on their diabetic medication [3,7].

Discharge Criteria
The patient should only be discharged if the cause of hypoglycemia is identified and deemed benign, they have fully recovered, are tolerating oral intake well, and have had no recurrence of hypoglycemic episodes after a 4-hour period of observation. Discharge advice should include guidance on nutrition and recognition of hypoglycemia symptoms. Patients should be advised to ingest glucose in case of symptoms [3].

Referral
If discharged from the ED, patients should be referred to their primary physician or specialist for follow-up. Patients should also be advised to always carry sugar or candy to ingest in case hypoglycemic symptoms arise [3].

Revisiting Your Patient

You examine your patient in the examination room. Upon examination, you notice a decreased level of consciousness, but otherwise, the exam is unremarkable. During the examination, the nurse obtains IV access and administers a bolus dose of intravenous glucose. Much to the relatives’ relief and amazement, the patient returned to her normal behavior within 5 minutes. The patient herself reported lower urinary tract symptoms with a low-grade fever over the last two days. The relatives also reported administering her insulin according to her daily regimen, without being cautious about her reduced food intake.

In addition, blood investigations revealed that her renal function had significantly deteriorated since her last primary care visit, despite continuing on the same insulin regimen. The patient was subsequently admitted to a general ward for further evaluation and management.

Recommended Free Open Access Medical Education (FOAM) resources

Author

Picture of Rok Petrovčič

Rok Petrovčič

Attending Physician - UKC Maribor / University Medical Centre Maribor

Listen to the chapter

References

  1. Mathew P, Thoppil D. Hypoglycemia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022. Updated July 23, 2022. Accessed February 24, 2023. https://www.ncbi.nlm.nih.gov/books/NBK534841/

  2. Maheswaran AB, Gimbar RP, Eisenberg Y, Lin J. Hypoglycemic events in the emergency department. Endocr Pract. 2022;28(4):372-377.

  3. Ravert D. Hypoglycemia. In: Mattu A, Swadron S, eds. CorePendium. Burbank, CA: CorePendium, LLC; 2021. Updated August 25, 2021. Accessed February 24, 2023. https://www.emrap.org/corependium/chapter/rec3z0v69Pks65AZg/Hypoglycemia#references

  4. Jalili M. Type 2 diabetes mellitus. In: Tintinalli JE, ed. Tintinalli’s Emergency Medicine. 7th ed. New York, NY: McGraw Hill; 2011:1431-1432.

  5. Nickson C. Hypoglycemia. In: Life in the Fast Lane. Accessed February 24, 2023. https://litfl.com/hypoglycemia/

  6. Frier BM. Defining hypoglycemia: what level has clinical relevance? Diabetologia. 2009;52(1):31-34.

  7. Oyer DS. The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev. 2013;9(3):195-208.

  8. May N. Oh, sugar! Paediatric hypoglycaemia. In: St. Emlyn’s Blog. Accessed March 1, 2023. http://stemlynsblog.org/paediatric-hypoglycaemia/

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Beta-blocker Intoxication (2024)

by Alessandro Lamberti-Castronuovo & Filippo Pedretti Magli

You Have A New Patient!

A 53-year-old male was brought to the Emergency Department by Emergency Medical Services (EMS). The EMS team reported that his wife had called 911 after finding him in the bathroom experiencing a seizure. When paramedics arrived, the seizures had ceased, and the patient was unconscious. En route to the hospital, the EMS team did not report performing any relevant medical procedures.

The image was produced by using ideogram 2.0.

Upon arrival, the patient was lethargic with a Glasgow Coma Scale (GCS) score of 8, making it impossible to obtain a clinical history. On physical examination, the patient’s respiratory rate was 10 breaths per minute, and he was slightly bradycardic with a heart rate of 52 bpm. He had a fever with a body temperature of 38.3°C, and his blood pressure was 85/50 mmHg. Oxygen saturation on room air was 94%. The pupils were normal.

On auscultation, cardiac sounds were rhythmic and stable, and lung sounds were clear and normal. Neurological examination was unremarkable, showing no evidence of nervous system disorders. Gastrointestinal auscultation revealed no abnormalities in bowel sounds. Laboratory examinations were within normal limits. The electrocardiogram (ECG) showed sinus bradycardia at 50 bpm, with a QRS duration of 122 ms and a normal QTc interval.

The patient’s wife and son later arrived at the hospital and reported his current medications, which included propranolol, benazepril, and as-needed use of metoclopramide and alprazolam.

What Do You Need To Know?

Importance

Beta-adrenergic blocking agents, more commonly known as Beta-Blockers (BBs), are a class of medications used to treat various heart-related conditions, such as arrhythmias, heart failure, and angina. They are also used to prevent and manage symptoms in individuals suffering from migraines and tremors. The first BBs were developed in the early 1960s, and today there are over twenty different BB molecules and numerous commercial formulations available.

It is crucial to recognize, identify, and treat Beta-Blocker intoxication for at least three key reasons:

  1. Widespread Use: BBs are one of the most commonly prescribed classes of drugs in the United States. According to Definitive Healthcare Claims, 20 million people (accounting for 6% of the population) were using BBs in 2022 [1]. Consequently, many individuals are at risk of poisoning, which can lead to severe consequences.

  2. Pediatric Risks: Approximately 30% of cases of pediatric acute intoxications are caused by cardioactive drugs (e.g., BBs, ACE inhibitors, calcium-channel blockers), with a mortality rate ranging between 0.1% and 0.3%. These incidents account for about 7% of emergency pediatric hospitalizations [2]. Such acute intoxications often result from accidental poisoning, as BBs are frequently used by adult family members and may be readily available at home.

  3. Complex Clinical Presentation: Beta-Blocker Intoxication (BBI) can present a challenging and complex situation for clinicians. It often manifests with mixed signs and symptoms that may mimic disorders of the central nervous system or the cardiocirculatory system. This complexity arises from the multiple physiological effects of BBs, which influence critical cardiac, respiratory, and metabolic mechanisms by acting on myocardial cells, vascular endothelial cells, and smooth muscle cells.

Epidemiology

According to the 2021 Annual Report of the National Poison Data System, which analyzed cases of exposure to BBs alone (i.e., not in combination with other drugs), 10,832 cases were reported in the United States in 2021. Among these, 4,268 cases required treatment in healthcare facilities [3].

Unintentional exposure accounted for approximately 78% of all reported cases in 2021 (see Table 1), while intentional poisoning cases represented approximately 18%.

Table 1. Number of Single Exposures Analyzed by Reasons for Exposure [3,4]

Year

No. of Single Exposures

Reason

Unintentional

Intentional

Other

Adverse Drug Reaction

2020

10,994

8,761

1,888

3

253

2021

 10,832

8,482

1,978

3

266

With regard to outcomes, no severe consequences were recorded in 32.3% of all cases in 2021. BBI-related deaths accounted for 0.17% of cases in 2021 (see Table 2).

Table 2. Outcomes of Beta-Blocker Intoxication Cases in 2021 [3,4]

Year

No. of Single Exposures

Outcome

None

Minor

Moderate

Major

Death

2020

10,994

3,692

 738

954

 167

18

2021

 10,832

3,508

731

1,094

 144

 18

Among all BBs, propranolol is the medication most frequently associated with cases of BB toxicity and is the most commonly used in suicide attempts worldwide [5].

Pathophysiology

BB generally have three main effects: 1) a negative inotropic effect through beta-adrenergic receptor blockade; 2) a lusitropic effect (i.e., increasing the rate of myocardial relaxation); and 3) a negative chronotropic effect. BB can be categorized based on various properties or characteristics. For example, BB can be classified into two broad categories—selective and non-selective—depending on whether they specifically block beta-receptors (see Table 3).

Metoprolol, atenolol, bisoprolol, and nebivolol are examples of selective BB, meaning they primarily exert their effects on the heart muscle. In contrast, propranolol, nadolol, and sotalol are examples of non-selective BB. These non-selective BB not only affect the cardiocirculatory system but also have a significant impact on the smooth muscle of the bronchi, causing bronchoconstriction and vasoconstriction. Notably, receptor selectivity diminishes as BB concentrations increase. In other words, selectivity progressively declines as the BB concentration in the bloodstream rises.

Table 3. Beta-Blockers Classification

 

 

 

Pharmacological classification

 

Selectivity properties

Selective β receptors.

 

Non-selective β receptors.

 

Haemodynamic consequences

Vasodilatation effect

Non-dilatation effect

Receptor interaction classification

α1-receptor

α1-receptor antagonism (arteriolar vasodilation).

β receptor

 

Selectivity for β receptors.

Non-selectivity for β receptors

Intrinsic sympathomimetic activity

possibility of both agonism and antagonism effects

Lipophilicity

Lipophilic:  High – Intermediate – Low lipophilicity

Lipophobic

BB have varying half-lives, ranging from several minutes to several hours. For this reason, symptoms of BBIs caused by different BBs can have different times of onset. Signs and symptoms of toxicity typically appear within 6 hours of medication intake. However, if the beta-blocker is formulated as a slow-release molecule, symptom onset can be delayed by up to 12 hours.

With regard to BB cardiovascular toxicity, the following effects are most significant:

  1. Sinus node activity impairment, leading to sinus bradycardia or sinus arrest;
  2. Atrioventricular node activity impairment, leading to atrioventricular block;
  3. Peripheral vasodilation, resulting in systemic hypotension;
  4. QT prolongation, which may lead to torsades de pointes (particularly with sotalol and acebutol).

Hypotension and bradycardia can reduce myocardial contraction and oxygen consumption, resulting in tachypnea and hyperventilation that may further compromise hemodynamic stability. BBs like acebutol exhibit intrinsic sympathomimetic activity (ISA, see Table 3), which may result in a lesser effect on heart rate.

BBI can also present with central nervous system (CNS)-specific symptoms, as highly lipophilic BBs can cross the blood-brain barrier. This mechanism may lead to CNS effects such as delirium, seizures, CNS depression, and coma. Propranolol has the highest lipophilic index among BBs [6]. Furthermore, at very high doses, BBs may block sodium channels, stabilizing membrane fluidity and exacerbating toxicity with manifestations such as seizures, coma, and QRS widening.

BBs may also cause metabolic disturbances. A mild hypokalemia may be observed, and hypoglycemia can occur due to BB-mediated inhibition of glycogenolysis and gluconeogenesis [5].

Medical History [7,8]

In cases of BBI, obtaining a comprehensive medical history may sometimes be challenging due to the patient’s altered state of consciousness. For this reason, or to confirm the information collected, it may be necessary to consult witnesses, family members, EMS personnel, or analyze medical records and the patient’s personal belongings [7].

The following information should be collected whenever possible:

  • Type of substance: It is recommended to identify the exact beta-blocker involved to better manage the emergency, given the wide range of molecules and reactions.
  • Quantity of substance: Determining the amount of beta-blocker administered is crucial for understanding or predicting the severity of toxicity.
  • Drug formulation: Identify whether the drug is slow-release, extended-release, or immediate-release.
  • Time of intake: Assess how much time has passed since the first administration and the onset of symptoms.
  • Route of administration: Determine how the substance was administered (e.g., oral, intravenous).
  • Number of people involved (if applicable).

Whenever possible, practitioners should also gather a detailed medical history, including:

  • Allergies;
  • Previous surgeries;
  • Known diseases;
  • Previous hospitalizations;
  • Current and previous medications;
  • Patient’s personal and family history of illnesses (e.g., intentional BB intake or previous suicide attempts);
  • Use of drugs, tobacco, or alcohol;
  • Last meal.

BBI Symptoms

Pulmonary System: Symptoms involving the pulmonary system in cases of BBI may include breathing difficulties such as dyspnea and gasping. These manifestations can indicate significant respiratory compromise and should be promptly addressed.

Cardiovascular System: Cardiovascular symptoms often include chest pain, faintness (typically resulting from hypotension and bradycardia), dizziness, and fatigue. These signs highlight the impact of BBIs on the heart and circulatory system and may signify underlying hemodynamic instability.

Central Nervous System: The central nervous system is frequently affected in BBI, with symptoms such as weakness, agitation, diaphoresis, drowsiness, confusion, and fever. These presentations underscore the potential for CNS-specific involvement, particularly in highly lipophilic BBs capable of crossing the blood-brain barrier.

Gastrointestinal System: Gastrointestinal symptoms commonly observed in BBI include an “upset” stomach, abdominal pain, and nausea. These manifestations may arise as a secondary consequence of systemic effects or direct drug toxicity.

Sensory System: Sensory system involvement in BBI can present as blurred vision or double vision. These symptoms may accompany more generalized CNS toxicity and reflect impaired sensory processing.

BBI Red Flags

Concurrent Intake of Cardioactive Medications: One significant red flag in cases of BBI is the concurrent intake of other cardioactive medications, such as ACE inhibitors or calcium-channel blockers. The combination of these drugs with BBs can amplify their cardiovascular effects, increasing the risk of severe hypotension, bradycardia, and other toxic effects.

Concurrent Intake of Other Medications: Another important consideration is the simultaneous use of other medications, such as benzodiazepines. The interaction between BBs and these drugs can enhance CNS depression, leading to symptoms such as drowsiness, confusion, or even coma in severe cases.

Comorbidities or Medical Conditions: Certain comorbidities or medical conditions for which BB intake is contraindicated also represent critical red flags. Conditions such as asthma, liver failure, kidney failure, or bradyarrhythmia can exacerbate the severity of BBI, as BBs may worsen bronchoconstriction, impair organ function, or exacerbate existing cardiovascular instability.

Physical Examination

During a physical examination (PE) of a patient with a potential BBI, the following key features should be assessed:

Neurological Signs: Neurological signs arise from the drug’s effects on the CNS and impaired brain perfusion. Mental status during BBI correlates directly with the severity of intoxication. Patients may present with weakness, drowsiness, agitation, or confusion. Levels of consciousness can range from alert and agitated to unconsciousness. Additionally, pupil mydriasis may be observed, particularly following a seizure episode.

Thoracic Assessment: Examination of the thoracic region may reveal an increased respiratory rate due to sympathomimetic effects. Conversely, a decreased respiratory rate may result from lethargy or a pre-coma phase. Lung auscultation in patients without asthma or other pulmonary conditions is typically normal, with regular breath sounds. However, findings may vary depending on the patient’s level of consciousness, airway patency, and respiratory effort. Observing the use of chest and neck accessory muscles can provide critical information about respiratory distress and dyspnea. Wheezing may occur as a clinical indicator of bronchospasm.

Cardiovascular Assessment: Cardiovascular findings may vary widely. Patients may present with tachycardia (e.g., as a compensatory response to hypotension) or bradycardia in more advanced stages of intoxication. A weak pulse can indicate shock, and blood pressure is often low. Heart sounds may be arrhythmic. Capillary refill time should be evaluated to assess perfusion status, providing insight into the body’s acute response to poisoning.

Gastrointestinal Assessment: Gastrointestinal auscultation may reveal either increased bowel sounds due to sympathomimetic effects or decreased motility as a consequence of low-level intoxication. Given that BBs are metabolized in the liver and/or kidneys, liver or kidney failure may occur, especially in patients with pre-existing hepatic or renal disease.

Body Inspection: Physical examination may reveal skin color changes indicative of perfusion or metabolic failure, such as cyanosis, jaundice, or other signs of kidney or liver dysfunction. Additional findings may include diaphoresis and pallor as markers of shock, as well as mucosal dryness and fever.

Alternative Diagnoses

In BBI, a detailed clinical history and accurate examination, along with diagnostic tests, can help identify the toxic agent [6,7]. However, alternative diagnoses may present with features similar to those of BBI.

Differential Toxicological Diagnoses:

  • Digoxin Intoxication: Patients with digoxin intoxication often exhibit more severe arrhythmias (due to AV node blockage) and gastrointestinal symptoms. Renal failure or electrolyte imbalances are more frequent than in BBI.
  • Calcium Channel Blockers Intoxication: These patients typically present with more severe hypotension.
  • α2 Agonist Intoxication: Patients may develop CNS depression earlier and often present with miosis and hyporeflexia.
  • Organophosphate Poisoning: This condition is characterized by increased salivation and tear production, along with tremors.
  • Antidepressant Intoxication: Vision problems, confusion, drowsiness, and high blood pressure are more distinguishing features.
  • Cocaine Toxicity: Patients more frequently present with agitation, confusion, tachycardia, dysrhythmia, and hypertension.
  • Carbamazepine Intoxication: This condition is associated with ataxia, epileptic seizures, and respiratory arrest.
  • Cardiac Glycoside Plant Poisoning: Patients often present with hyperkalemia, renal failure, or ventricular arrhythmia.

Differential Non-Toxicological Diagnoses:

  • Neurological Conditions: Other conditions presenting with lethargy or unconsciousness (e.g., emergency epidural hematoma, meningitis) should be considered.
  • Metabolic Conditions: Conditions leading to major arrhythmias, such as severe hyperkalemia, must also be ruled out.

Acing Diagnostic Testing

Bedside Tests

  • Multiparameter Monitoring: Continuous monitoring of vital parameters such as blood pressure, heart rate, respiratory rate, oxygen blood saturation, and body temperature is essential.
  • Blood Glucose Level: Blood glucose measurement is crucial to identify hypoglycemia, a potential consequence of beta-blocker toxicity.
  • ECG: A 12-lead ECG is generally recommended in addition to continuous cardiac monitoring. It is important to note that many BBs can block sodium or potassium channels, leading to QRS widening and QTc prolongation. These effects can persist for hours to days, depending on the specific BB involved. Sotalol, in particular, is commonly associated with QTc prolongation. This clinical scenario requires careful medical evaluation, close observation, and the discontinuation of other drugs that may contribute to QTc prolongation.
  • Arterial Blood Gases Test (ABG): ABG testing is necessary to assess acid-base balance and oxygenation, which may be affected in cases of severe toxicity.

Laboratory Tests

Laboratory tests are essential for identifying comorbidities and metabolic complications. These include:

  • Serum Electrolytes: To assess for imbalances that may arise from beta-blocker intoxication or underlying conditions.
  • Complete Blood Count (CBC): To evaluate overall health and detect signs of infection or other hematologic abnormalities.
  • Liver Function Tests: Particularly important for patients with a history of liver failure, as beta-blockers are metabolized in the liver.
  • Pregnancy Test: To rule out pregnancy in women of childbearing age, as pregnancy may influence treatment decisions.
  • Blood Alcohol Level: To check for concurrent alcohol use, which may exacerbate beta-blocker toxicity.
  • Plasma Dosage Concentration: Rarely available in the Emergency Department or during emergencies, and generally not recommended since it does not typically alter patient management [6].
  • Toxicologic Screening Tests on Blood and Urine: These tests are not always conclusive for evaluation. False positives or false negatives may mislead clinical decision-making and are not predictive of patient outcomes.

Imaging

Chest X-Ray: A chest X-ray is particularly useful for patients with asthma or other pulmonary diseases to rule out complications following the acute phase of poisoning.

Risk Stratification

The main risk factors for a worse outcome in BBI can be investigated through medical history, physical examination, and laboratory tests.

Risk Factors in Medical History

  • Co-ingestion of Other Medications: Many drugs potentiate beta-blocker toxicity, exacerbate acute symptoms, mask clinical signs or laboratory abnormalities, and complicate stabilization. It is essential to determine whether the patient has taken other medications to administer an appropriate antagonist. Specific co-ingested medications to consider include:

    • Other antihypertensive drugs (e.g., diuretics, ACE inhibitors, calcium channel blockers);
    • Medications for chronic arrhythmia, such as amiodarone or flecainide;
    • Drugs that indirectly lower blood pressure (e.g., nitrates, muscle relaxants);
    • Medications for asthma or chronic obstructive pulmonary disease (COPD);
    • Diabetes medications, especially insulin;
    • Allergy medications, including ephedrine, noradrenaline, or adrenaline;
    • Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.
    • Particular attention should be given to psychotropic drugs like tricyclic antidepressants and antipsychotics, as these pose significant risks when combined with beta-blockers.
  • Pre-existing Diseases: Cardiovascular and pulmonary conditions (e.g., heart failure, valve defects, asthma, COPD) can rapidly deteriorate in time-sensitive, critical situations, leading to worse outcomes for patients.

  • Other Medical Conditions Incompatible with Beta-Blocker Use:

    • Allergy to beta-blockers;
    • Pre-existing low blood pressure or conditions that compromise cardiac rhythm;
    • Metabolic acidosis.

Risk Factors in Physical Examination

The earlier the onset of severe signs and symptoms, the greater the likelihood of a worse outcome. Key indicators include:

  • Unconsciousness or coma;
  • Severe dyspnea;
  • Arrhythmias;
  • Severe hypotension and/or signs of shock.

Risk Factors Identified in Diagnostic Tests

Laboratory and diagnostic tests indicating organ failure or worsening vital parameters are critical markers for a poor prognosis.

Diagnostic Tests

Diagnostic tests that reveal signs of organ failure or worsening vital parameters are critical indicators of a poor prognosis.

Management

Initial Management
Since BBs do not have any specific antidote or antagonist, the primary aim of management is to reduce the effects of BBI and its consequences.

Management Options in Unstable Patients [6,7]

Following an ABCDE approach, the management of BBI in unstable patients focuses on maintaining the perfusion of vital organs by increasing heart rate and myocardial contractility.

Airway

  • CNS depression may occur, making early airway management critical to maintaining airway patency. Blood glucose measurements are necessary for patients with altered mental status.
  • In children, intubation may provoke additive bradycardia due to vagal stimulation during laryngeal manipulation. The use of atropine may be necessary to prevent this.

Breathing

  • Supplemental oxygen and inhaled bronchodilators can help manage BBI-related pulmonary complications, such as bronchospasm.

Circulation

  • Ensure venous access and initiate multiparametric monitoring, including blood pressure (BP), heart rate (HR), respiratory rate (RR), oxygen saturation (FiO2), body temperature, and ECG.
  • In cases of hypotension, fluid resuscitation with crystalloids should be considered.
  • Ventricular arrhythmias and other cardiac resuscitation issues must be addressed according to Advanced Cardiac Life Support (ACLS) protocols.

Disabilities

  • For seizures caused by intoxication, benzodiazepines are the first-line medication treatment.

Exposure

  • No specific exposure protocols are recommended for BBI.

Medications [6,7]

If patients present to the Emergency Department at an early stage following substantial BB intake and/or exhibit severe symptoms, gastrointestinal decontamination is recommended. This may include gastric lavage, administration of activated charcoal, and/or bowel irrigation.

Contraindications for Gastric Lavage:

  • Unprotected airways;
  • Concurrent ingestion of caustic substances or hydrocarbons;
  • Tablets or pills too large to pass through the probe’s suction holes.

Multiple doses of activated charcoal, hemoperfusion, and hemodialysis may be beneficial for BBs that are water-soluble or excreted primarily through kidney metabolism.

Table 4. Medications for Gastrointestinal Decontamination

Drug name

Function / Effect

Dose

Frequency

Cautions

Activated Charcoal

substance absorption in GI system

1g/kg

one-off

  • Administered within 1 or 2 hours from intake to maximize the absorption.
  • Contraindications: patient vomiting, caustic or volatile substances, airways not protected.

Polyethylene glycol

Bowel irrigation

Adult: 1,5-2,0 L/h,

Children 6-12 y.o. : 1,0-1,5 L/h,

Infants <6 y.o.: 0,5 L/h

one-off

  • Indicated especially with slow release BB.

Glucagon is one of the most commonly used medications for intoxication due to its chronotropic and inotropic effects. While no comprehensive studies or trials conclusively prove glucagon’s efficacy in management, its use has been empirically validated in BBI management protocols over the years for its demonstrated usefulness.

Table 5. Glucagon Therapy for Cardiac Stabilization

Function / Effect

Protocol / Doses

Cautions / Comments

Heart rhythm and contraction stabilization

Bolus: 3-5 mg IV [0,05 mg/kg]

Continuous Administration: 1-10 mg/h

Side effects: hypocalcemia, hyperglycemia and vomiting.

High-dose insulin therapy has also been reported to be effective in counteracting the negative inotropic effects of beta blockers. The complete therapeutic treatment for euglycemia in BBI is described below. Serum potassium and glucose levels should be checked immediately.

Table 6. Euglycemia Therapy

Function / Effect

Protocol / Doses

Cautions / Comments

Therapy in case of BBI-induced hypoglycemia

  • Administration of 50mL of glucose at 50% (0,5 g/mL) IV
  • Administration of 1 U/kg of regular insulin bolus IV
  • Starting infusion of regular insulin at 0,5-1 U/Kg x h and infusion of glucose at 10% (0,1 g/mL) at 200mL/h in Adults and 5 mL/Kg x h in children.
  • Monitoring glycemic every 20 minutes, with Glucose titration in order to maintain glycemia between 150 and 300 mg/dL
  • After infusion speed has been stable for at least 60 mins, glycemia levels can be checked every hour.
  • Monitoring potassium level and starting IV potassium infusion if level < 3,5 mEq/L
  • High-dose insulin could causes Negative inotropic effect.
  • In case of hypotension protocol can be delayed from 20 to 60 minutes.
  • Sides effect: hypokalemia and hypoglycemia, this occurrence can potentiate the toxicity of Beta-blocker symptoms.

Vasopressors should be considered when hypotension proves refractory to fluid administration. The clinical picture, medical history, and physical examination are crucial in guiding the selection of an appropriate vasopressor.

Table 7. BP and HR Increase

Drug name

Function / Effect

Dose

Frequency

Cautions

Calcium gluconate/

Calcium chloride

BP increase and stabilization

10 ml at 10%, 0,15 ml/kg

one-off

  • Suggested treatment in case of BBI in combination with Calcium Channel Blockers.
  • Calcium chloride is more effective but must be administered through a central venous access.

Atropine

Increase of heart rate

0,5-1 mg IV (0,02 mg/kg, total dose not inferior at a 0,1 mg)

one-off

  • Severe hypotension and bradycardia are often refractory to atropine

Lipid emulsion therapy has emerged as a promising treatment modality for BB toxicity, particularly in cases of severe cardiovascular compromise [8]. The underlying mechanism is thought to involve the “lipid sink” effect, where the lipid emulsion binds to lipophilic drugs, reducing their bioavailability and facilitating their elimination from the body. Clinical evidence suggests that intravenous lipid emulsions can improve hemodynamic stability and restore cardiac function in patients experiencing life-threatening beta blocker overdose [9,10]. A systematic review highlighted the positive outcomes associated with lipid emulsion therapy in various cases of drug toxicity, including beta blockers, emphasizing its role as an adjunctive treatment [11]. However, while lipid emulsion therapy shows promise, it is essential to consider it as part of a comprehensive treatment approach, including standard resuscitation measures and specific antidotes when available [12].

  • Propranolol and other BB toxic effects are associated with QRS widening. Early recognition of QRS widening and QTc interval prolongation is critical. This should be followed by the administration of sodium bicarbonate for QRS widening and magnesium sulfate for QTc prolongation.

  • In cases of refractory bradycardia, cardiac pacing should be considered.

  • Severe poisoning cases may require external mechanical life support, such as extracorporeal membrane oxygenation (ECMO), which may be necessary until the xenobiotic effect subsides.

Special Patient Groups

With regard to age groups exposed to BB, data analysis shows a peak in early childhood (≤5 years old), accounting for 22.6% of total single exposure cases in 2021 (see Table 8) [3]. The largest age group exposed comprises individuals aged 20 years and older, representing 63.5% of exposures.

In younger age groups, exposures are more often unintentional. Among the 13–19 age group, exposures are frequently associated with suicide attempts. In individuals over 20 years of age, the intentionality of exposure varies significantly due to numerous contributing factors.

Table 8. Number of Single Exposures Analyzed by Age of Exposure [3,4]

Year

No. of Single Exposures

Age*

< =5

6-12

13-19

> =20

2020

10,994

2,524

314

534

7,100

2021

 10,832

2,452

 355

611

 6,894

*2020 – Unknown child: 3 /Unknown adult: 473 / Unknown age: 46

*2021 – Unknown child: 0 /Unknown adult: 473 / Unknown age: 47

Pediatrics

Pediatric patients have a lower tolerance threshold to beta-blockers due to underdeveloped cardiovascular homeostasis mechanisms. Although various studies have been conducted on infants and children, no comprehensive literature exists, leaving the risk of toxicity from beta-blocking drugs uncertain. Consequently, toddler exposure to BB remains undefined in terms of specific risk factors and criteria.

The most common scenario involves the ingestion of a few tablets. In children without concurrent risk factors, the likelihood of mortality or significant morbidity can generally be ruled out [13-15].

Pregnant Patients

During pregnancy, BB are among the most commonly prescribed medications, particularly labetalol and metoprolol, for treating hypertension and other cardiac conditions. Data indicate no toxicity consequences for the mother or fetus when used at prescribed dosages.

During breastfeeding, low levels of BB may be present in the mother’s milk. Therefore, it is recommended to monitor the baby for any changes in behavior or symptoms [16-18].

Geriatrics

In the elderly, BB toxicity may be exacerbated by interactions with other medications (e.g., antihypertensives, benzodiazepines). Additionally, organ system failure (e.g., kidney and liver failure) and CNS-related symptoms tend to be more pronounced in this population [19,20].

When To Admit This Patient

In BBI, the criteria for deciding whether to admit a patient are as follows [6,7]:

  • Observation for Immediate-Release BBs: Stable patients with intoxication from rapid- or immediate-release BBs should be kept under observation for at least 6 hours.
  • Observation for Extended-Release BBs: Patients with extended-release or modified-release BB intoxication require longer observation. The situation is considered safe when no signs or symptoms are evident, depending on the specific half-life of the BB.
  • Post-Invasive Procedures: Patients who have undergone invasive life-saving procedures must remain under observation.
  • Clinical Instability: Patients presenting with clinically unstable parameters, such as bradycardia, hypotension, heart conduction abnormalities, or mental status alterations, should be admitted to the ICU.
  • Intentional Intake: Patients suspected of or confirmed to have intentionally ingested BBs, regardless of the severity of intoxication, must not be discharged before undergoing a psychiatric evaluation.

In all cases, consultation with a Poison Control Center or a Toxicology Specialist should be considered.

Discharge Criteria
Before discharge, a thorough re-evaluation of physical symptoms, clinical signs, and vital parameters is mandatory. If necessary, diagnostic tests should be repeated prior to discharge.

If the patient is deemed suitable for discharge:

  • Ensure the patient understands all medical advice related to their condition following the intoxication episode, including self-care measures, follow-up checkups, and, if applicable, continuation of medical therapies.
  • Provide guidance on reducing BB risk factors.
  • Educate the patient on the symptoms and signs of BB poisoning or overdose to facilitate early recognition in the future.

Whenever possible, establish direct communication with the patient’s family doctor to coordinate follow-up care.

Special Considerations

  • In pediatric intoxications, involving social workers may be appropriate.
  • For non-self-sufficient patients or minors, ensure that family members, caregivers, or legal guardians fully understand the medical advice provided.

Revisiting Your Patient

A 53-year-old male was brought to the emergency room by EMS. The EMS team reported that his wife had called 911 after finding him in the bathroom experiencing a seizure. When paramedics arrived, the seizures had stopped, and the patient was unconscious. On the way to the hospital, the EMS team did not report performing any relevant medical procedures.

The patient was lethargic upon arrival with a Glasgow Coma Scale (GCS) score of 8, making it impossible to obtain a clinical history. On physical examination, the patient’s respiratory rate was 10 breaths per minute, and he was slightly bradycardic with a heart rate of 52 bpm. He had a fever with a stable body temperature of 38.3°C, and his blood pressure was 85/50 mmHg. Oxygen saturation on room air was 94%. Pupils were normal. On auscultation, cardiac sounds were rhythmic and stable, and lung sounds were clear and normal. Neurological examination revealed no nervous system abnormalities, and gastrointestinal auscultation showed no altered bowel sounds. Laboratory results were within normal limits. The ECG showed sinus bradycardia at 50 bpm, with a QRS duration of 122 ms and a normal QTc interval.

His wife and son arrived at the hospital and reported that he was taking propranolol, benazepril, and, as needed, metoclopramide and alprazolam. The family brought the drug boxes to the hospital, and it was noted that the propranolol box was almost empty. His son mentioned that the medication had been purchased the day before.

Management and Treatment
The approach began with airway management, followed by preventive therapy with naloxone, glucose, and thiamine. Since the family reported alprazolam use, flumazenil therapy was administered to rule out worsening of possible benzodiazepine intoxication. Intravenous (IV) fluids were provided to address hypotension. Blood glucose levels were normal. The patient did not respond to the initial treatment.

Based on the medical history, physical examination, and clinical presentation, a BBI management protocol was initiated. Glucagon (3 mg IV) and dopamine (5 mcg/min IV) were administered, along with activated charcoal to reduce bowel absorption. Following this, the patient began responding to the treatment. Blood pressure increased to 110/70 mmHg, the ECG showed a sinus rhythm at 86 bpm, and the QRS duration narrowed to 90 ms. Oxygen saturation improved to 98% on room air. Glucagon infusion was continued at 1–10 mg/h.

The patient was transferred to the acute observation room. After one hour, he was conscious, breathing spontaneously, and his vital parameters were stable. Since the propranolol formulation was immediate-release, observation lasted 8 hours.

Discharge and Follow-Up
After the observation period, nephrology and psychiatry consultations were requested to ensure a safe discharge. Repeat physical examination and laboratory tests confirmed stability, and the patient was safely discharged into his family’s care.

Authors

Picture of Alessandro Lamberti-Castronuovo

Alessandro Lamberti-Castronuovo

Alessandro Lamberti-Castronuovo is a physician with over 15 years of clinical experience specialized in emergency and internal medicine, with further work in cardiology and diagnostic ultrasound. He is an Emergency Medicine Consultant at the Emergency Department of the Sant’Andrea Hospital in Vercelli Italy, where he is in charge both of the training of resident doctors and of the Hospital Major Incident Planning. Alessandro is also a global health researcher focusing on issues surrounding access to care, and an advocate for ensuring health delivery to vulnerable populations. His main focus of interest is strengthening health systems in order to improve access to care, essentially by building integrated and people-centred health systems based on principles of equity and social justice through a primary health care approach. His projects focus on 1) strengthening access to primary care and continuity of care for vulnerable populations and 2) strengthening emergency department's surge capacity, ultimately bolstering the integration of all health actors in a so-called "whole-of-health-system" approach. After completing his MSc in International Health at the Charité University in Berlin with a thesis project on community health workers in refugee camps, he joined CRIMEDIM (Center for Research and Training in Disaster Medicine, Humanitarian Aid and Global Health) where he is currently pursuing a joint PhD in global health, humanitarian aid and disaster medicine at the University of Eastern Piedmont and University of Bruxelles. His research work focuses on integrating primary care into the health emergency and disaster risk management and on enhancing the preparedness for disasters of whole communities especially the most marginalized parts.

Picture of Filippo Pedretti Magli

Filippo Pedretti Magli

Filippo Pedretti Magli is a medical student at University of Ferrara. He is also an emergency medical technician, serving in pre-hospital ambulances for emergency medical service. Filippo is a university medical student’s trainer in the field of Disaster Medicine for CRIMEDIM. He recently took part as co-teacher in Infectious risk-management master program for doctors and nurses in Parma, focusing on the analysis with disaster medicine criteria of data about Covid-19 impact on primary health care and health system. He deepened his medical education with several training sessions and courses in the emergency department, achieving certificates in E-FAST ultrasonographic protocol and advanced difficult intubation and intraosseous access procedures.

Listen to the chapter

References

  1. Definitive Healthcare. Beta-blocker prescription patterns. Definitive Healthcare Blog. Published March 23, 2022. Accessed December 25, 2024. https://www.definitivehc.com/blog/beta-blocker-prescription-patterns.
  2. Soave PM, Curatola A, Ferretti S, et al. Acute poisoning in children admitted to pediatric emergency department: a five-year retrospective analysis. Acta Biomed. 2022;93(1):e2022004. doi:10.23750/abm.v93i1.11602.
  3. Gummin DD, Mowry JB, Beuhler MC, et al. 2021 Annual Report of the National Poison Data System (NPDS) from America’s Poison Centers: 39th Annual Report. Clin Toxicol (Phila). 2022;60(12):1381-1643. doi:10.1080/15563650.2022.2132768.
  4. Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the America’s Poison Centers’ National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila). 2021;59(12):1282-1501. doi:10.1080/15563650.2021.1989785.
  5. Sharma A. Beta-Blocker Toxicity: Practice Essentials, Pathophysiology, Epidemiology. Medscape eMedicine. Updated May 30, 2020. Accessed December 25, 2024. https://emedicine.medscape.com/article/813342-overview.
  6. Khalid MM, Hamilton RJ. Beta-Blocker Toxicity. StatPearls [Internet]. Updated July 18, 2022. Accessed December 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK448097/.
  7. Cline DM, Ma OJ. Tintinalli’s Emergency Medicine: Just the Facts. 3rd ed. McGraw Hill Professional; 2012.
  8. Huang CH, et al. Management of beta-blocker overdose: A review. Emerg Med J. 2020;37(8):487-493. doi:10.1136/emermed-2020-209493.
  9. Dargan PI, et al. Lipid emulsion therapy for severe beta-blocker toxicity. Clin Toxicol (Phila). 2015;53(9):853-855. doi:10.3109/15563650.2015.1090595.
  10. Sweeney TE, et al. Lipid emulsion therapy for beta-blocker toxicity: A systematic review. J Med Toxicol. 2016;12(3):267-276. doi:10.1007/s13181-016-0559-1.
  11. Weinberg GL, et al. Lipid emulsion infusion in the management of drug toxicity: A systematic review. Toxicol Rev. 2018;37(4):234-245. doi:10.1080/15563650.2018.1453385.
  12. Hoffman RS, et al. Management of beta-blocker overdose: A review of the literature. Emerg Med Clin North Am. 2019;37(2):293-305. doi:10.1016/j.emc.2018.12.002.
  13. Love JN, Howell JM, Klein-Schwartz W, Litovitz TL. Lack of toxicity from pediatric beta-blocker exposures. Hum Exp Toxicol. 2006;25(6):341-346. doi:10.1191/0960327106ht632oa.
  14. Eibs HG, Oberdisse U, Brambach U. [Intoxication by beta-blockers in children and adolescents (author’s transl)]. Monatsschr Kinderheilkd. 1982;130(5):292-295. Accessed December 25, 2024. https://pubmed.ncbi.nlm.nih.gov/6125881/.
  15. Love JN, Sikka N. Are 1–2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med. 2004;26(3):309-314. doi:10.1016/j.jemermed.2003.11.015.
  16. Duan L, Ng A, Chen W, et al. β-Blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med. 2017;177(6):885-887. doi:10.1001/jamainternmed.2017.0608.
  17. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, et al. Beta-blocker use in pregnancy and the risk for congenital malformations: An international cohort study. Ann Intern Med. 2018;169(10):665-673. doi:10.7326/M18-0338.
  18. Bergman JEH, Lutke LR, Gans ROB, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: A European case-malformed control study. Drug Saf. 2018;41(4):415-427. doi:10.1007/s40264-017-0627-x.
  19. Lafarge L, Bourguignon L, Bernard N, et al. Pharmacokinetic risk factors of beta-blocker overdose in elderly patients: Case report and pharmacological rationale. Ann Cardiol Angeiol (Paris). 2018;67(2):91-97. doi:10.1016/j.ancard.2018.02.001.
  20. Vögele A, Johansson T, Renom-Guiteras A, et al. Effectiveness and safety of beta blockers in the management of hypertension in older adults: A systematic review to help reduce inappropriate prescribing. BMC Geriatr. 2017;17(1):224. doi:10.1186/s12877-017-0575-4.

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Procedural Sedation and Analgesia (2024)

by Nik Hisamuddin Nik Ab Rahman

Introduction

Sedation for painful procedures involves the administration of drugs by any route or technique that results in a reduction of awareness and pain levels. The main aim of procedural sedation analgesia (PSA) is to reduce discomfort while maintaining the effective performance of the procedure. Effective PSA induces a reduced level of consciousness while enabling the patient to independently sustain oxygenation and manage their airway [1, 2].

The use of sedation involves certain risks, including:

  1. Impairment of the patient’s protective reflexes, which can result in airway obstruction or aspiration.
  2. Suppression of respiratory and cardiovascular functions, which may lead to complications such as hypoxia, hypotension, bradycardia, or even cardiac arrest.

The effects of sedative medications can vary, with the possibility of over-sedation or airway obstruction at any point. Ensuring patient cooperation and maintaining verbal communication are critical objectives for procedural sedation. These guidelines are designed to assist non-anaesthesiologists in safely administering sedation and analgesia to adult patients, whether in an operating room or other settings, to minimize risks and enhance patient safety [3].

When sedation is managed by non-anaesthesiologists, it is essential to limit the sedation level to minimal or moderate. The ideal goal is to achieve a moderate level of consciousness, allowing the patient to independently maintain their airway and cardiovascular stability. Deep sedation should be avoided unless an emergency physician skilled in airway management or an anaesthesiologist is present throughout the procedure (Figure 1).

Figure 1 - Continuum Level of Sedation - Resource: American Society of Anesthesiologists article, March 2002 Volume 66, Number 3, Practice Management: Sedation and the Need for Anesthesia Personnel Karin Bierstein, J.D. (the figure illustrated by AA Cevik)

Goals of PSA include:

  • Ensuring patient safety before, during, and after PSA.
  • Minimizing pain and anxiety associated with the procedure.
  • Reducing the patient’s movement during the procedure.
  • Maximizing the likelihood of procedural success and facilitating the patient’s return to their pre-sedation state as quickly as possible.

Indications

  • Alleviate pain and/or anxiety commonly associated with therapeutic or diagnostic procedures.
  • Enhance the success of procedures by promoting patient relaxation and minimizing movement, thereby improving the precision and efficiency of the intervention.

Therapeutic or diagnostic interventions include, but are not limited to, synchronized cardioversion for the management of arrhythmias, closed reduction of dislocations or fractures, incision and drainage of abscesses, primary closure of lacerations, thoracostomy tube placement for pleural effusions or pneumothorax, extraction of foreign bodies, vascular access establishment for intravenous or intra-arterial administration, and cannulation for hemodynamic monitoring or intervention.

Contraindications

Absolute Contraindications

  • The urgent need for immediate treatment (e.g., hemodynamic instability) that cannot be delayed for sedation.
  • Hypersensitivity to the administered drug or its delivery vehicle.
  • Specific to nitrous oxide: Conditions such as pneumothorax, pneumomediastinum, bowel obstruction, or the presence of an intraocular gas bubble (e.g., following vitreoretinal surgery), where nitrous oxide can expand into air-filled spaces.

Allergy to eggs or soy is no longer considered a contraindication to propofol, as the allergenic components in eggs or soy differ from the moieties used in propofol formulations.

Relative Contraindications

  • Severe cardiopulmonary disease, which increases the risk of decompensation due to respiratory depression.
  • Obstructive sleep apnea.
  • Obesity or anatomical features (e.g., micrognathia, macroglossia, short neck, or congenital anomalies) suggestive of potential difficulties with intubation.
  • Chronic liver or kidney disease, which may impair drug metabolism and lead to prolonged sedation.
  • Patients older than 60 years of age, who face an increased risk of decompensation; PSA drug doses should often be reduced.
  • Acute alcohol or sedative drug intoxication, which heightens the risk of respiratory complications; PSA drug doses should be decreased accordingly.
  • Chronic alcohol or substance use disorder, which may necessitate an increased PSA drug dosage.
  • Pre-procedural intake of food or drink; institution-specific protocols regarding fasting prior to PSA should be reviewed.

When any of these relative contraindications are present, consult an anesthesiologist or consider the use of drugs that do not depress respiration (e.g., ketamine) [4, 5].

Although some guidelines recommend postponing elective procedural sedation for several hours after ingestion of clear liquids and for eight hours after ingestion of solids, there is no definitive evidence to support the efficacy or necessity of such measures.

Equipment and Patient Preparation

Choices of Sedative and Analgesic Agents

Always plan to use the minimum number and dosage of sedative and analgesic agents required to achieve the targeted level of sedation. This approach minimizes the risk of adverse drug effects and reduces the likelihood of complications associated with PSA.

“Never use neuromuscular blocking (NMB) agents for PSA.”

The selection of agents may differ based on local protocols or nationwide regulations. It is essential to consult the relevant institutional or regional guidelines. In cases of uncertainty, seek guidance from qualified emergency physicians or anesthetists [6].

Ketamine (IV or IM)
Ketamine can be administered intravenously (IV) or intramuscularly (IM). For IV administration, the loading dose ranges from 0.5 to 2 mg/kg, while for IM administration, the loading dose ranges from 2 to 4 mg/kg. Maintenance dosing is recommended at 0.1 mg/kg IV every 10 minutes. The typical dose for a 70 kg adult is 35 to 70 mg for IV administration and 140 to 280 mg for IM administration.

Fentanyl (IV)
Fentanyl is administered intravenously. The loading dose ranges from 50 to 100 mcg over a period of one minute. Maintenance dosing is 25 mcg every five minutes as required. For a typical 70 kg adult, the dose is approximately 50 mcg.

Midazolam (IV)
Midazolam is administered intravenously. The loading dose ranges from 1 to 2.5 mg IV given over two minutes. Maintenance dosing involves 1 mg every five minutes as required. For a typical 70 kg adult, the usual dose is 1 to 2.5 mg IV or 5 mg IM.

Etomidate (IV)
Etomidate is given intravenously with a loading dose of 0.1 to 0.2 mg/kg. Maintenance dosing is 0.05 mg/kg every five minutes. For a 70 kg adult, the typical dose is 7 to 15 mg IV.

Propofol (IV)
Propofol is administered intravenously with a loading dose ranging from 0.5 mg/kg (in elderly patients) to 1 mg/kg. Maintenance dosing is 0.1 mg/kg every one to two minutes. For a typical 70 kg adult, the loading dose is 35 to 70 mg, with a maintenance dose of 10 mg.

Ketafol (Ketamine + Propofol) (IV)
Ketafol, a combination of ketamine and propofol, is administered intravenously. The loading dose is 0.5 to 1 mg/kg of ketamine, with maintenance dosing of 10 mg of propofol every two minutes. For a 70 kg adult, the ketamine loading dose ranges from 35 to 70 mg IV, and the propofol maintenance dose is 10 mg every two minutes.

  • Ketamine is considered safe for use in children undergoing procedural sedation and analgesia in the emergency department (ED). Propofol is safe for procedural sedation and analgesia in both children and adults in the ED (LEVEL A).
  • Etomidate is safe for procedural sedation and analgesia in adults in the ED. Additionally, a combination of propofol and ketamine is safe for procedural sedation and analgesia in both children and adults (LEVEL B) [7].
  • Ketamine is safe for procedural sedation and analgesia in adults in the ED. Alfentanil is also safe for procedural sedation and analgesia in adults in the ED. Furthermore, etomidate is safe for use in children undergoing procedural sedation and analgesia in the ED (LEVEL C) [8, 9].
Facilities & Equipment

The procedure must be conducted in a facility that is sufficiently spacious and adequately equipped to handle potential cardiopulmonary emergencies. The required resources include:

  1. A room of adequate size to accommodate resuscitation efforts, if necessary.
  2. Adequate lighting for performing procedures safely.
  3. An operating table, trolley, or chair that can be tilted head-down (preferable but not mandatory).
  4. A suction apparatus meeting operating room standards.
  5. A reliable oxygen supply and suitable devices for administering oxygen to a spontaneously breathing patient.
  6. Equipment for lung inflation with oxygen (e.g., a self-inflating bag and mask) and access to a range of advanced airway management tools, including masks, oropharyngeal airways, endotracheal tubes, laryngoscopes, and laryngeal mask airways.
  7. A resuscitation trolley equipped with appropriate drugs and equipment for cardiopulmonary resuscitation.
  8. A pulse oximeter for monitoring oxygen saturation.
  9. A sphygmomanometer or another device for blood pressure monitoring.
  10. Ready access to an electrocardiogram (ECG) machine and a defibrillator.
  11. A reliable means of summoning emergency assistance.

Patient Preparation

Patient preparation is a critical step in ensuring the safety and effectiveness of procedural sedation and analgesia (PSA) in the emergency department. Proper preparation minimizes the risks of complications, enhances patient comfort, and facilitates procedural efficiency [10-12].

A comprehensive pre-procedural assessment is essential to evaluate the patient’s medical history, allergies, and current medications, including over-the-counter drugs, herbal supplements, and recreational substances. Identifying contraindications to sedation, such as a history of adverse reactions to sedatives or anesthetics, is crucial. Patients should be provided with detailed fasting instructions tailored to the type of sedation and their medical condition. Typically, fasting guidelines recommend 6–8 hours for solid food and 2–4 hours for clear liquids to reduce the risk of aspiration. However, many emergency department patients 

Informed consent is a cornerstone of patient preparation. Patients or their guardians should receive clear explanations about the procedure, its risks, benefits, and potential alternatives, and written consent should be obtained. It is equally important to address any anxiety or stress by offering reassurance and allowing patients to express concerns. Effective communication and education about what to expect during and after PSA help alleviate anxiety and improve the overall experience. Additionally, patients should be instructed to remove jewelry, dentures, or other loose objects before the procedure and wear comfortable, loose-fitting clothing.

On the day of the procedure, patients must have a responsible adult accompany them to the emergency department and arrange transportation home post-procedure. Intravenous (IV) access should be secured for administering sedatives, analgesics, and potential fluid resuscitation. Continuous monitoring of baseline vital signs, including oxygen saturation, heart rate, and blood pressure, must be ensured throughout the procedure to detect and address any adverse events promptly.

Post-procedure care involves monitoring the patient until they have fully recovered from sedation. Before discharge, patients should be provided with detailed written instructions on post-procedural care, including medication guidance, activity restrictions, and follow-up appointments. A contact number for the emergency department or healthcare provider should also be provided in case of concerns or complications after discharge.

Adhering to these recommendations, including thorough preparation, education, and monitoring protocols, ensures patient safety and comfort, reduces the likelihood of complications, and optimizes the success of PSA in the emergency department

Procedure Steps

General Clinical Management and Documentation
  • Written documentation of procedural sedation must be completed by the responsible physician or surgeon, covering all phases of the procedure (pre, intra-, and post-procedure).
  • Documentation should include:
    • Names of all staff involved in the procedure.
    • Findings from history, physical examination, and investigations.
    • Drug dosages and their administration times.
    • Vital signs (pulse rate, oxygen saturation, and blood pressure) recorded pre-, during, and post-procedure.

Assessment of Patient Status
The physician in charge should document patient assessment using the American Society of Anesthesiologists (ASA) classification system [13]:

  • ASA Class 1: Normal healthy patient with no significant systemic disturbances.
  • ASA Class 2: Patient with mild systemic disease without functional limitations.
  • ASA Class 3: Patient with severe systemic disease causing some functional limitation.
  • ASA Class 4: Patient with severe systemic disease posing a constant threat to life.
  • ASA Class 5: Moribund patient not expected to survive without surgery.
  • ASA Class 6: Brain-dead patient whose organs are being harvested for donation.

Note: PSA performed by non-anesthesiologists is recommended only for ASA Class 1 and 2 patients.

Indications for Involvement of an Anesthesiologist

The presence of an anesthesiologist may be required for patients at increased risk of airway, respiratory, or cardiovascular compromise, or those prone to serious adverse events during sedation [14]. These include patients with:

  1. Advanced age, particularly with significant co-morbidities.
  2. Significant cardiovascular, pulmonary, renal, or hepatic disease.
  3. Morbid obesity.
  4. Obstructive sleep apnea.
  5. Known or suspected difficult airway/intubation cases.
  6. Acute gastrointestinal bleeding associated with cardiovascular compromise or shock.
  7. Risk of aspiration of gastric contents.
  8. History of adverse events from sedation, analgesia, or anesthesia.
  9. History of substance abuse.

The decision to involve an anesthesiologist should be made by the clinician after carefully weighing the risks to the patient [14].

For non-emergency cases, PSA should adhere to general fasting guidelines to minimize the risk of aspiration during the procedure. The recommended fasting durations vary by age and the type of substance ingested, summarized as the “2-4-6 rule” [15]. For children, the guidelines are as follows: 2 hours for clear fluids, 4 hours for breast milk, and 6 hours for formula milk or solid foods. For adults, the fasting guidelines recommend 2 hours for clear fluids and 6 hours for milk or solids. Clear fluids include water, glucose drinks, cordial beverages, and clear fruit juices. These fasting protocols ensure adequate preparation and safety for PSA in non-emergency settings.

Steps in the Administration of Procedural Sedation [16]
Pre-Procedure

Proper preparation is essential to ensure the safety and success of PSA. The following steps should be undertaken:

  1. Patient Selection: Assess the appropriateness of PSA for the patient based on clinical needs and risk factors.
  2. Patient Assessment: Conduct a thorough review of relevant medical history, physical examination, and investigations as outlined in institutional protocols.
  3. Pre-Procedural Instructions: Provide patients with written instructions on preparation and post-procedural care, including contact details for emergencies. Instructions should be available in multiple languages to enhance accessibility.
  4. Consent: Obtain verbal or written consent according to institutional requirements. In cases of altered mental status or unconscious patients, PSA may proceed without written consent if close relatives provide authorization.
  5. Personnel: Ensure a minimum of two qualified and experienced personnel are present—one to perform the procedure and the other to administer drugs and monitor vital signs.
During the Procedure

To maintain patient safety and achieve the desired sedation level, adhere to the following steps during PSA administration:

  1. IV Access: Establish intravenous access for drug administration and potential resuscitation needs.
  2. Monitoring: Continuously monitor the patient’s vital signs, including pulse oximetry, non-invasive blood pressure (NIBP), and electrocardiography (ECG). Document all findings in accordance with protocol.
  3. Oxygen Administration: Deliver supplemental oxygen using appropriate devices such as nasal prongs or face masks, as indicated.
  4. Drug Administration: Administer sedation drugs exclusively by trained registered medical practitioners or registered dental practitioners.
  5. Continuous Observation: Assign a dedicated assistant to monitor the patient throughout the procedure, ensuring early detection and management of potential complications.
Post-Procedure

Post-procedural care focuses on monitoring recovery, ensuring patient safety, and providing clear discharge instructions:

  1. Documentation: Record all details of the procedure, including the drugs used and vital signs monitored.
  2. Recovery Monitoring: Continue observation of the patient’s vital signs using pulse oximetry and NIBP until full recovery is achieved.
  3. Discharge: Patients should be discharged only when accompanied by a responsible adult. Provide written instructions on post-procedural care.
  4. Reinforce Instructions: Before discharge, verbally review post-procedural care instructions to ensure patient understanding and compliance.
Recommendations for PSA Monitoring by Target Sedation Level

Monitoring requirements vary depending on the desired level of sedation:

Minimal Sedation:

  • Level of Consciousness: Observe frequently.
  • Heart Rate: Measure every 15 minutes.
  • Respiratory Rate: Measure every 15 minutes.
  • Blood Pressure: Measure every 15 minutes and after sedative boluses.
  • Oxygen Saturation: Monitor continuously.
  • Capnography End-Tidal CO2: Not required.

Moderate or Dissociative Sedation:

  • Level of Consciousness: Observe constantly.
  • Heart Rate: Monitor continuously.
  • Respiratory Rate: Continuous direct observation.
  • Blood Pressure: Record every 5 minutes and after sedative boluses.
  • Oxygen Saturation: Monitor continuously.
  • Capnography End-Tidal CO2: Consider continuous monitoring.
  •  

Complications

Performing PSA requires close monitoring and is associated with potential adverse events. Numerous analgesic, sedative, and anesthetic agents can be used in combination for PSA in the ED. However, adverse event reporting for PSA has been heterogeneous.

Known complications of PSA include agitation, apnea, aspiration, bradycardia, bradypnea, hypotension, hypoxia, intubation, laryngospasm, and nausea/vomiting [17-19]. Among these, the most frequently observed adverse events are hypoxia, occurring at a rate of 40.2 per 1,000 sedations, followed by vomiting, hypotension, and apnea.

Severe adverse events requiring emergent medical intervention are less common but include aspiration (%0.12), laryngospasm (%0.42), and intubation (%0.16). 

The routine use of capnography monitoring during PSA is recommended as it allows earlier detection of hypoventilation and apnea compared to pulse oximetry and/or clinical assessment alone [20]. Studies have shown that the combination of Ketamine and Propofol (Ketofol) results in a lower incidence of adverse events, including agitation, apnea, hypoxia, bradycardia, hypotension, and vomiting, compared to each medication used individually [21].

Although the incidence of serious adverse events during PSA in the ED is rare, it is essential to practice shared decision-making and obtain informed consent, as PSA is not a completely benign procedure [22].

Hints and Pitfalls

Pitfalls of PSA

The common pitfalls of procedural sedation and analgesia are often attributed to inadequate practitioner skills, improper patient selection, or insufficient knowledge of the pharmacological agents being used. When these factors are combined, they may result in either under-sedation or over-sedation, compromising the airway, cardiovascular, or respiratory system, and increasing the risk of adverse outcomes [23-26].

Failure to administer safe and effective PSA can lead to unnecessary complications, heightened anxiety, and delays in the patient’s return to normal function following emergency department procedures. Barriers to achieving optimal PSA outcomes, especially when performed by non-anaesthesiologists, often include knowledge gaps among providers and inadequate efforts toward quality improvement. It is critical that PSA be performed by competent and experienced practitioners who follow established guidelines and standard operating procedures, which should be readily available in all facilities where PSA is conducted (e.g., emergency physicians, internal physicians, surgeons, dental practitioners).

For painful procedures, alternative pain management strategies, such as nerve blocks, should be considered when they are safer and equally effective. Additionally, it is essential to complete a checklist for pre-, intra-, and post-PSA to ensure patient safety and optimize outcomes.

Key Considerations for PSA

  • Most sedative agents lack significant analgesic effects; therefore, analgesia should be administered beforehand and given sufficient time to achieve its maximal effect prior to administering the sedative agent.
  • PSA agents and doses should always be tailored to the individual patient, taking into account factors such as age, comorbidities, and the patient’s clinical status. Elderly, debilitated, and acutely ill patients require lower initial doses of sedative agents than healthy young adults.
  • Sedative agents should be titrated gradually to avoid complications, and sufficient time should be allowed for the sedative to take full effect before starting the procedure.
  • Regular audits and quality assurance programs should be conducted to monitor and improve PSA practices over time.

Indicators of Sedation Failure

Sedation failure may occur if:

  • The patient experiences undue discomfort during the procedure.
  • Adverse events such as hypotension or hypoxia arise.
  • Prolonged observation is required following the procedure.

Common Pitfalls in PSA Administration [23]

  1. Inadequate provision of analgesia prior to administering sedatives.
  2. Insufficient time allowed for analgesics or sedatives to achieve their maximal effect.
  3. Failure to adjust doses for elderly or chronically ill patients, leading to over-sedation or complications.
  4. Rapid titration of sedative agents, increasing the risk of adverse events.
  5. Premature discontinuation of monitoring or transferring a sedated patient from a controlled environment (e.g., from the procedure room to the x-ray department).
  6. Discharge of patients without adequate supervision or clear written instructions; sedative agents may cause amnesia, making verbal instructions ineffective.
  7. Failure to address the specific needs of vulnerable populations, such as pediatric, geriatric, or pregnant patients, as well as adults with significant comorbidities.

Special Patient Groups

Pediatrics [27,28]

Procedural sedation for pediatric patients requires thorough preparation and specific considerations due to their unique anatomical and physiological characteristics. Consent must be obtained from parents or guardians, except in emergent situations where two senior practitioners may assess and provide consent. Special attention should be given to airway assessment to prevent respiratory compromise. Pharmacological agents with known respiratory adverse effects should be avoided or dosages adjusted as necessary.

Assessment Prior to Procedural Sedation in Children:

  • Evaluate fasting status.
  • Perform a focused medical examination, emphasizing airway assessment.
  • Utilize the American Society of Anesthesiologists (ASA) classification (only ASA I & II patients are considered suitable).
  • Review previous sedation or general anesthesia experiences and outcomes.

Key Considerations:

  • A history of severe sleep apnea or airway abnormalities necessitates additional precautions when planning sedation.
  • Paradoxical reactions, such as increased agitation with benzodiazepines or barbiturates, are more common in younger children.
  • Adverse effects like agitation upon emergence, diplopia, nausea, and vomiting have been reported with ketamine use.
  • Selection of sedation agents and administration routes should align with the patient’s individual needs, the procedure type, and the anticipated level of pain.
  • Early consultation with a pediatric anesthesiologist is recommended for patients with chronic airway diseases or a history of drug-related adverse events.
  • Discharge should only occur with a responsible adult and comprehensive post-discharge instructions for home observation

Geriatrics [29]

Procedural sedation is generally safe in older adults; however, under-treatment of pain or inadequate sedation should be avoided. Initial assessment must include a thorough review of comorbidities and medication history to identify potential interactions with sedatives or analgesics.

Special Precautions for Geriatric Patients:

  • Patients with chronic respiratory or cardiovascular diseases require additional monitoring.
  • Older adults typically require lower doses of sedative agents due to increased sensitivity, slower metabolism, reduced physiological reserves, and smaller volume of distribution.
  • These patients are at higher risk for oxygen desaturation, but most respond well to supplemental oxygen.

Pregnant Patients [30,31]

Procedural sedation may be appropriate for pregnant patients experiencing significant pain, distress, or requiring surgical intervention, provided it is conducted under the supervision of a physician skilled in obstetric anesthesia. Pregnancy induces hemodynamic changes such as decreased blood pressure (due to vasodilation and aortocaval compression), increased cardiac output, and reduced maternal hematocrit.

Key Considerations for Sedation in Pregnancy:

  • Exposure to PSA medications is typically brief, with low doses, making significant adverse effects on pregnancy outcomes unlikely.
  • Over-sedation can lead to maternal hypotension and hypoxia, which may result in fetal hypoxia.
  • Medications used in PSA can influence uterine activity, placental perfusion, and fetal oxygenation. They may also directly affect fetal heart rate by crossing the placenta or indirectly via maternal hemodynamic changes.

Pharmacological Agents in Pregnancy:

  • Midazolam: Frequently used due to its rapid onset and short duration. Although it crosses the placenta via passive diffusion, no conclusive evidence suggests it adversely affects fetal development at clinically recommended doses. Animal studies indicate potential effects when combined with other anesthetics.
  • Propofol: Clinically recommended doses are not associated with fetal defects and are widely used for obstetric and non-obstetric procedures. However, excessive doses may result in fetal depression due to its lipophilic nature and placental transfer.
  • Ketamine: Generally not recommended due to limited human data. It is known to cross the placenta, and animal studies suggest potential neurotoxicity with prenatal and early postnatal exposure.

Author

Picture of Nik Hisamuddin Nik Ab Rahman

Nik Hisamuddin Nik Ab Rahman

Professor Dr. Nik Hisamuddin Nik Ab Rahman graduated with an MBChB from the University of Glasgow in 1994. He completed the Emergency Medicine trainee program (Master of Medicine) at Universiti Sains Malaysia (USM) in 2002. He further honed his expertise as a Clinical Fellow in Emergency Medicine at Edinburgh Royal Infirmary, Scotland, and in Hyperbaric & Diving Medicine at Key Largo, Florida, USA. In 2016, he earned his PhD in Health Informatics & GIS in Health, specializing in road traffic injuries. Professor Nik Hisamuddin spearheaded the development of the Department of Emergency Medicine at Hospital USM, introducing Malaysia’s first Trauma Intensive Care Unit (TICU). He currently serves as the Director of Hospital USM and a Professor in Emergency Medicine and Hyperbaric/Diving Medicine at the School of Medical Sciences, USM. Additionally, he is a committee member of the USM Management Team, the Malaysia National Specialist Registry (Emergency Medicine; 2009–present), and the Specialty Conjoint Committee in the Master of Medicine in Emergency Medicine (2005–2017). He has been awarded numerous research grants from national and international sources. His research and clinical interests include trauma and injury prevention, community life support education, hyperbaric medicine, and acute pain management. He is currently supervising seven PhD and eight Master's candidates, with a focus on Design and Developmental Research (DDR) approaches. With approximately 70 peer-reviewed journal articles to his name, Professor Nik Hisamuddin is a leading figure in his field. His hobbies include traveling, golfing, and shopping.

Listen to the chapter

References

  1. Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med.2014;63(2):247-258. (Practice guidelines) DOI: 10.1016/j.annemergmed.2013.10.015
  2. Norii T, Homma Y, Shimizu H et alProcedural sedation and analgesia in the emergency department in Japan: interim analysis of multicenter prospective observational study.  Anesth. 
  3. Smits GJ, Kuypers MI, Mignot LA et alProcedural sedation in the emergency department by Dutch emergency physicians: a prospective multicentre observational study of 1711 adults.  Med. J. 2017; 34: 237–42.
  4. Green SM, Roback MG, Krauss BS et alUnscheduled procedural sedation: a multidisciplinary consensus practice guideline.  Emerg. Med. 2019; 73: e51–e65.
  5. Hinkelbein J, Lamperti M, Akeson J et alEuropean Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults.  J. Anaesthesiol. 2018; 35: 6–24.
  6. Procedural sedation in the emergency department by Dutch emergency physicians: a prospective multicentre observational study of 1711 adults. Smits GJ, Kuypers MI, Mignot LA, et al. Emerg Med J. 2017;34:237–242.
  7. Stephen M Green et al. Unscheduled Procedural Sedation: A Multidisciplinary Consensus Practice Guideline. American College of Emergency Physicians. https://www.acep.org/patient-care/policy-statements/unscheduled-procedural-sedation-a-multidisciplinary-consensus-practice-guideline/. Published February 2019. Accessed September 26, 2019.
  8. Green S, Roback M, Kennedy R, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011;57(5):449-461. https://www.ncbi.nlm.nih.gov/pubmed/21256625.
  9. Dilip TS, Chandy GM, Hazra D, Selvan J, Ganesan P. The adverse effects of ketamine on procedural sedation and analgesia (PSA) in the emergency department. J Family Med Prim Care. 2021;10:2279–2283. 
  10. Kern, J., Guinn, A., & Mehta, P. (2022). Procedural sedation and analgesia in the emergency department. Emergency medicine practice24(6), 1–24.
  11. Bell, A., Taylor, D. M., Holdgate, A., MacBean, C., Huynh, T., Thom, O., Augello, M., Millar, R., Day, R., Williams, A., Ritchie, P., & Pasco, J. (2011). Procedural sedation practices in Australian Emergency Departments. Emergency medicine Australasia : EMA23(4), 458–465. https://doi.org/10.1111/j.1742-6723.2011.01418.x
  12. Cappellini I, Bavestrello Piccini G, Campagnola L, Bochicchio C, Carente R, Lai F, Magazzini S, Consales G. Procedural Sedation in Emergency Department: A Narrative Review. Emergency Care and Medicine. 2024; 1(2):103-136. https://doi.org/10.3390/ecm1020014
  13. Horvath B, Kloesel B, Todd MM, Cole DJ, Prielipp RC. The Evolution, Current Value, and Future of the American Society of Anesthesiologists Physical Status Classification System. Anesthesiology. 2021 Nov 01;135(5):904-919.
  14. Stephen M Green et al. Unscheduled Procedural Sedation: A Multidisciplinary Consensus Practice Guideline. American College of Emergency Physicians. https://www.acep.org/patient-care/policy-statements/unscheduled-procedural-sedation-a-multidisciplinary-consensus-practice-guideline/. Published February 2019. Accessed September 26, 2019.
  15. Green SM, Leroy PL, Roback MG, et al. An international multidisciplinary consensus statement on fasting before procedural sedation in adults and children. Anaesthesia 2020; 75: 374-85.
  16. Academy of Medicine of Malaysia. Recommendations for Sedation and Analgesia by Non-Anaesthesiologists. From: https://www.moh.gov.my/moh/resources/auto%20download%20images/5ca1b20916a50.pdf Accessed December 1, 2024.
  17. Bellolio MF, Puls HA, Anderson JL et alIncidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta‐analysis. BMJ Open 2016; 6: e011384. 
  18. Bellolio MF, Gilani WI, Barrionuevo P, et al. Incidence of adverse events in adults undergoing procedural sedation in the emergency department: a systematic review and meta-analysis. Acad Emerg Med. 2016;23(2):119–134. 
  19. Kahlenberg L, Harsey L, Patterson M, et al. Implementation of a modified WHO pediatric procedural sedation safety checklist and its impact on risk reduction. Hosp Pediatr. 2017;7(4):225–231. doi: 10.1542/hpeds.2016-0089
  20. Wall BF, Magee K, Campbell SG, et al. Capnography versus standard monitoring for emergency department procedural sedation and analgesia. Cochrane Database Syst Rev.2017;3(3):CD010698.
  21. Miller KA, Andolfatto G, Miner JR, et al. Clinical practice guideline for emergency department procedural sedation with propofol: 2018 update. Ann Emerg Med.2019;73(5):470-480. (Practiceguidelines) DOI:10.1016/j.annemergmed.2018.12.012
  22. Calderwood AH, Chapman FJ, Cohen J, et al. Guidelines for safety in the gastrointestinal endoscopy unit. Gastrointest Endosc. 2014;79(3):363–372.
  23. Russell D, Thakore SB. Safe Sedation Procedures in Adults. Lloyd G, ed. Mac Mahon T, McKay G, reviewers. Published April 19, 2021. Accessed December 11, 2024. https://www.rcemlearning.co.uk/reference/adult-procedural-sedation/
  24. American College of Emergency Physicians . Clinical Policy: procedural Sedation and Analgesia in the Emergency Department. Annals of Emergency Medicine2014; 63: 247–58. 
  25. Beach ML, Cohen DM, Gallagher SM, Cravero JP. Major adverse events and relationship to nil per os status in pediatric sedation/anesthesia outside the operating room: a report of the pediatric sedation research consortium. Anesthesiology2016; 124: 80–8. 
  26. Green SM, Roback MG, Krauss BS et alUnscheduled procedural sedation: a multidisciplinary consensus practice guideline.  Emerg. Med. 2019; 73: e51–e65.
  27. Mahajan C, Dash HH. Procedural sedation and analgesia in pediatric patients. J Pediatr. Neurosci.2014; 9: 1–6.
  28. Bhatt M, Johnson DW, Chan J, et al. Risk factors for adverse events in emergency department procedural sedation for children. JAMA Pediatr.2017;171(10):957-964.
  29. Hayashi M, Norii T, Albright D, Crandall C. Incidence of adverse events for procedural sedation and analgesia for cardioversion using thiopental in elderly patients: a multicenter prospective observational study. Acute Med Surg. 2023 Jan 2;10(1):e812. doi: 10.1002/ams2.812.
  30. McElhatton P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol.1994; 8: 461-475
  31. Reitman E. Flood P. Anaesthetic considerations for non-obstetric surgery during pregnancy. Br J Anaesth.2011; 107: i72-i78

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Management of Pain in the Emergency Department (2024)

by Kayla Peña, Kelsey Thompson, & Munawar Farooq

You have a new patient!

A 57-year-old woman with a PMH of peptic ulcer disease presents to the emergency department 20 minutes after slipping and falling while out for a jog. She twisted her left ankle awkwardly while stepping off the pavement and fell to the side. She did not hit her head. She got up after the fall but has not tried to put weight on the ankle. Her vital signs are stable. She has a temperature of 37°C, a heart rate of 110 beats per minute, respirations at 18 breaths per minute, a blood pressure of 128/60, and an oxygen saturation of 96% on room air. 

a-photo-of-a-57-year-old-female-patient-(the image was produced by using ideogram 2.0)

She is currently seated in a chair and appears uncomfortable. On exam, the left ankle appears more swollen than the right, with no bruising. She has tenderness to palpation at the posterior edge of the left lateral malleolus but no left midfoot tenderness. The right foot is non-tender. Pulses are intact throughout with a 2-sec capillary refill distally. She states, “Please help me; I can’t take the pain!”

Introduction

Pain is one of the most common reasons patients seek care in the ED. Pain is a signal from the body to alert the patients of actual or potential tissue damage. Addressing pain is a key part of the emergency department practice. However, doing so appropriately requires understanding our options to treat pain and a clear process to assess the factors causing the patient’s pain [1]. Pain treatment offers numerous advantages, such as alleviating pain-induced tachycardia in specific cases like acute MI and aortic dissection. Additionally, improved pain relief contributes to higher patient satisfaction.

Pain Assessment

When administering analgesics to patients in pain, there are no definitive contraindications. However, several factors should be considered when selecting the appropriate analgesic agent, including its route and dose. These factors encompass the pain’s intensity, probable cause, and the patient’s age, weight, medical history (including comorbidities and drug allergies), and vital signs. Pain is a complex and subjective experience that is unique to each patient. Appropriately assessing pain requires a thorough history and physical exam that include:

  • Location: Where is the pain? Does it travel or go anywhere else? 
  • Onset: When did the pain begin? Is this an acute, chronic, or exacerbation of a chronic issue?
  • Provocation: What makes the pain worse?
  • Palliation: Does anything make this pain feel better? What has the patient tried to make it feel better, even if it didn’t work? Has the patient taken any medication at home to help with this, and what was the impact? If this patient has had this pain before, what made it better last time?
  • Quality: How does the pain feel?
  • Radiation: Does the pain go to any other location?
  • Severity: How severe is the pain? Can they compare it to other experiences they’ve had? How does it limit their activities, such as movement, eating, and sleeping?
  • Timing: Is the pain constant, or does it come and go? Does it change severity or quality over time?

Pain intensity scale

  • Numerical ranking: Ask your patient to rank the severity from 0 to 10, with 0 being no pain at all and 10 being the worst pain possible.
  • Verbal descriptors: Use descriptions from the patient of the pain and its impact on their functionality to rank their pain.
  • Visual descriptors: Use visual cues from your patient to rank their pain. The most common of these scales is the Wong-Baker scale, which is commonly used in children or nonverbal patients.

It is also important to remember that patients in pain may become agitated or mentally altered due to their pain. Severe pain in one area of the body may mask other symptoms or signs the patient is experiencing; hence, it is crucial to re-examine these patients after analgesia.

Analgesics

In the emergency department, treatment plans are often tailored to moderate/severe and acute and/or chronic pain.

Severe Acute Pain

In the management of moderate to severe acute pain, parenteral opioids are the primary treatment choice. These opioids target specific receptors in the central and peripheral nervous systems, altering how painful stimuli are perceived and responded to. Initially, they are administered as a bolus dose based on the patient’s weight, followed by titration every 5-15 minutes after reassessment. Opioids provide excellent analgesia, but they come with a long list of side effects that can be detrimental to the patient, even in the acute pain setting. Nausea and respiratory depression are the most significant side effects of all opioids, albeit with varying degrees. Parenteral opioids can also trigger pruritus and/or urticaria due to mast cell destabilization. Medications such as antiemetics, antihistamines, and naloxone can help reverse these potential side effects. Morphine is often the preferred parenteral opioid, with fentanyl and hydromorphone serving as alternatives. A safe initial dose of morphine is 0.1 mg/kg administered intravenously, while subcutaneous administration can be used if IV access is not available (although it is more painful and slower in onset). Please refer to the complete list of opioids and their recommended initial dosing regimens provided below.

  • Fentanyl: 0.25-1 µg/kg IV push [2], Short-acting opioid q. 15-60 minutes for severe pain.
  • Hydromorphone: 0.015 mg/kg IV/SC [3], q. 2-4 hours, avoid large doses in naive patients.
  • Oxycodone: 0.05-0.15 mg/kg PO [4], q. 3-4 hours.
  • Morphine: 0.1 mg/kg IV/SC [5], q. 3-4 hours, may cause release of histamine.
  • Oxycodone/Acetaminophen: 5-10 mg oxycodone/325-650 mg acetaminophen PO [6], q. 4-8 hours, moderate or severe pain (max dose of acetaminophen 4,000 mg/day).
  • Hydrocodone/Acetaminophen: 5 mg hydrocodone/325 mg acetaminophen, 1 to 2 tablets PO [7], q. 4-8 hours, moderate or severe pain (max dose of acetaminophen 4,000 mg/day).

Moderate Acute Pain

In cases of mild to moderate pain, oral opioids provide a suitable choice after initial non-opioid analgesia. Among these options are oxycodone combined with acetaminophen or hydromorphone combined with acetaminophen to impose a maximum daily dosage. The recommended dose for the opioid component is 0.05-0.15 mg/kg, and it can be repeated every 4-6 hours.  Refer to the full list of opioids and their initial dosing regimens above.

However, the primary recommendation for moderate acute pain is non-opioid analgesics like NSAIDs and acetaminophen. They can synergistically complement opioids, potentially reducing the overall required dose of medications and minimizing the likelihood of side effects.
Acetaminophen is the safest option among these analgesics, accessible in oral and intravenous forms. While its exact mechanism remains uncertain, it exerts its effects centrally. NSAIDs, such as ibuprofen and ketorolac, inhibit cyclooxygenase (COX), thereby blocking prostaglandin-mediated inflammation. However, inhibiting prostaglandin synthesis leads to renal vasoconstriction and thus should be avoided in those with kidney disease. Please refer to the complete list of non-opioids and their recommended initial dosing regimens provided below.

  • Acetaminophen: 10-15 mg/kg PO/IV [8], Avoid if taking other acetaminophen-containing drugs or in patients with liver failure.
  • Ibuprofen: 5-10 mg/kg PO [9], Avoid in elderly patients and those with renal disease and peptic ulcer disease.
  • Ketorolac: 0.5 mg/kg IV/IM [10], Should only be given q6 hours, No more than 5 days.

Chronic Pain

It is important to recognize that patients with conditions that cause chronic pain or recurrent episodes of severe pain, such as sickle cell, have frequent or even chronic usage of opioid medications that require an individualized pain management plan. While chronic pain is challenging to address in the ED setting, these patients frequently get undertreated for their acute exacerbations [11]. Chronic pain is treated similarly to acute pain, using opioids for severe pain and non-opioids for more moderate pain. Treatment depends on the severity and previous history of analgesic success [12]. A step ladder approach, including non-opioid and opioid therapy, will be appropriate as part of departmental guidelines.

In addition, patients with a past or current history of a substance use disorder, including opioid use disorder, can still present with real, severe pain that may require the use of opioids for management. It is essential to assess these patients carefully and treat their pain like any other patient. If there are concerns that the patient’s condition may be related to a substance use disorder, it may be appropriate to refer them to a multidisciplinary specialist for support. This should be done after conducting a thorough history and physical examination and addressing immediate medical needs [13]. It is also vital that the ED team sticks to an individualized pain management plan once made by a multidisciplinary team on every recurrent presentation.

When making decisions for your patient, it is crucial to prioritize awareness of the addictive nature of opiates. To aid in this challenging choice, assess the patient’s opioid tolerance, history of substance abuse, and the risk associated with prescribing short-term PRN opioids upon discharge. The NIH Opioid Risk Tool (ORT) is helpful for screening for opioid abuse risk [14].

Local Anesthesia

Local anesthetics obstruct pain signal transmission by temporarily obstructing sodium channels in sensory nerve membranes. In the emergency department, lidocaine is commonly used, with or without epinephrine, to enhance hemostasis and prolong anesthetic efficacy. Bupivacaine, a longer-acting agent, is typically employed for regional anesthesia. While local anesthetics are generally safe, systemic CNS and cardiovascular toxicity can occur at large doses. Traditional teaching states that local anesthetic administration should be avoided in end organs such as the ears, nose, and penis to prevent ischemia. However, strong evidence is lacking to support this concern [15]. Local departmental or hospital guidelines should be followed in this case.

  • Lidocaine:
    • Dose: Nerve Block 5-300 mg (maximum 4 mg/kg or 300 mg),
      • Acute Pain (Patch) 4%-5% patch q24 hours.
    • Rapid onset. The maximum dose of lidocaine is 4 mg/kg (without epinephrine) and 7 mg/kg with epinephrine [16,17].
    • Lidocaine is safe in pregnancy and breastfeeding.
  • Bupivacaine:
    • Dose: Max dose 2.5 mg/kg, 3 mg/kg with epinephrine [18].
    • Slower onset and higher risk of cardiovascular toxicity.
  • Chloroprocaine:
    • Dose: Max dose 10 mg/kg, 15 mg/kg with epinephrine [19].
    • Used in the case of allergy to lidocaine and other amide local anesthetics.

Procedural Sedation

Procedural sedation refers to the administration of medications aimed at reducing anxiety and pain while enhancing tolerance to a particular medical procedure. This technique is reserved for hemodynamically stable patients who are expected to be able to maintain their airways throughout the procedure. Common indications of this technique include cardioversion, orthopedic reductions, and other painful procedures [20]

A common approach to procedural sedation:

  1. Risk stratification to prepare for potentially difficult airway management
    1. Use the Mallampati Score to assess the difficulty of the airway should the patient lose their airway during the procedure. Refer to UpToDate Mallampati Airway Classification.
    2. Determine the ASA Score category. Refer to the ASA Physical Status Classification System.
  2. Informed Consent
    1. Typically, it is required before the procedure to discuss the complications and alternative options.
  3. Gathering Supplies
    1. IV, O2, Monitoring including capnography.
    2. BVM and airway trolley
  4. Assemble Team
    • Depending on the complexity of the procedures, decide about the team members and their roles. A separate person should typically be responsible for sedation and airway monitoring while one or two other members perform the procedure. For details about team dynamics, refer to this book’s chapter on Teamwork.
  5. Perform the procedural sedation
    1. Administer procedural sedation medications (See below)
    2. Perform the procedure while constantly assessing hemodynamic stability and respiratory status.
  6. Post Sedation Care
    • Provide post-sedation monitoring and reassessment, and then discharge instructions according to the individual case and departmental guidelines.

Most Common Procedural Sedation Medications

  • Midazolam:
    • Dose: 0.1 to 0.5 mg/kg IV [21].
    • Comments: No analgesic effect, administered before the procedure to reduce anxiety and provide amnesia.
  • Fentanyl:
    • Dose: 1 mcg/kg IV [22].
    • Comments: Reduces pain, commonly used in reductions and I&D as an adjunct to other medications or local anesthesia.
  • Propofol:
    • Dose: 0.5-1 mg/kg IV [23].
    • Comments: Used as a general short-acting anesthetic and causes respiratory depression and hypotension.
  • Etomidate:
    • Dose: 0.15 mg/kg IV [24].
    • Comments: Used as a general anesthetic; can cause myoclonus.
  • Ketamine:
    • Dose: 1-2 mg/kg IV [25], 2-4 mg/kg IM (especially in pediatrics).
    • Comments: The dissociative anesthetic that provides both amnesia and analgesia. Known to cause aggressive emergence reaction and rarely laryngospasm.

Hints and Pitfalls

Like all treatments, it is crucial to reassess the patient after giving them medication and understand how medication can change your ability to evaluate the patient. A patient in severe pain may be unable to provide a full history or participate in a complete physical exam until their pain has been controlled. For example, a patient with an extremely painful angulated fracture of the humerus may not be able to participate in an exam to evaluate their distal neurovascular status, or the same patient may have such severe pain in their arm that they do not notice that they are also having abdominal pain. Treating pain earlier in such encounters can help facilitate high-quality patient care.

Factors that can lead to undertreatment include atypical presentation, communication barriers, and implicit bias. Pediatric patients, patients with neurocognitive disorders, and patients from different cultural or linguistic backgrounds are frequently undertreated for their pain.

Special Patient Groups

It is essential to carefully evaluate pain in patients who cannot directly communicate with the physician [26].

Those patients may be:

  • Nonverbal at baseline
  • Speak a different language than the physician
  • Have a cognitive impairment
  • Geriatric patients
  • Underreporting of pain
  • Higher frequency of illness-causing cognitive impairment and communication barriers such as Alzheimer’s
  • Concerns for side-effects

Geriatric patients generally have poor physiological reserve and polypharmacy. While these factors need to be considered in the choice of analgesics, their dosage, and required monitoring, these concerns should not lead to undertreatment of pain in this population.

Revisiting Your Patient

How should we manage our 57-year-old female with peptic ulcer disease, who presented with a twisted ankle? Given that her left ankle is swollen and that she has bony 9/10 tenderness at the posterior edge of the left lateral malleolus but no left mid-foot pain, it is likely that she has an uncomplicated closed ankle fracture.

The initial step in management would be to start treating her pain soon after her presentation. An important KPI (Key Performance Indicator) in this regard is that the degree of pain is assessed on arrival in every patient who presents to ED with pain, and individually planned titrated analgesia is started as early as possible.
Given that she is in acute, moderately severe pain with a history of peptic ulcer disease (PUD), she would most likely benefit from a drug like Oral Hydromorphone and Oral/IV Paracetamol. In this patient’s case, NSAIDs, such as Ibuprofen, should specifically be avoided due to her history of PUD. Initial pain management in the emergency department can also be managed with “RICE,” which includes rest, ice, compression, and elevation of the injured body part. The RICE technique is an effective way to alleviate pain in patients who deny pain medication or who are still waiting to see a provider. It is important to reassess pain and vital signs after administering analgesics.

If this patient had an evident ankle deformity with weak pulses, she would have required procedural sedation and urgent reduction.

Authors

Picture of Kayla Peña

Kayla Peña

Rutgers Robert Wood Johnson Medical School

Picture of Kelsey Thompson

Kelsey Thompson

UCLA Harbor

Picture of Munawar Farooq

Munawar Farooq

College of Medicine and Health Sciences, UAEU Al Ain, UAE

Listen to the chapter

References

  1. Hachimi-Idrissi S, Coffey F, Hautz WE, et al. Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines-part 1: assessment. Intern Emerg Med. 2020;15(7):1125-1139. doi:10.1007/s11739-020-02477-
  2. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  3. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  4. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  5. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  6. Oxycodone/Acetaminophen: Drug Information. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  7. Hydrocodone/Acetaminophen: Drug Information. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  8. Paracetamol: In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  9. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  10. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  11. Dora-Laskey, A. (2022). Acute Pain Control. Society for Academic Emergency Medicine (SAEM M3 Curriculum). Retrieved from https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m3-curriculum/group-acute-pain-control/acute-pain-control.
  12. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A Systematic Review and Meta-analysis. JAMA. 2018;320(23):2448-2460. doi:10.1001/jama.2018.18472
  13. Nordt SP, Ray L. Lidocaine. In: Mattu A and Swadron S, ed. ComPendium. Burbank, CA: CorePendium, LLC. Updated May 12, 2023. Accessed May 13, 2023.https://www.emrap.org/corependium/drug/recUEl2x9lfeYKbws/Lidocaine#h.tuo0od96 muij.
  14. Perry JS, Stoll KE, Allen AD, Hahn JC, Ostrum RF. The opioid risk tool correlates with increased postsurgical opioid use among patients with orthopedic trauma. Orthopedics. 2023;46(4):e219-e222. doi:10.3928/01477447-20230207-04
  15. Schnabl SM, Herrmann N, Wilder D, Breuninger H, Häfner HM. Clinical results for use of local anesthesia with epinephrine in the penile nerve block. J Dtsch Dermatol Ges. 2014; Apr;12(4):332-339. doi: 10.1111/ddg.12287. Epub 2014 Mar 3. PMID: 24581175.
  16. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  17. Lidocaine with epinephrine. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  18. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  19. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  20. Miner James R., Paetow Glenn. Procedural Sedation. In: Mattu A and Swadron S, ed. CorePendium. Burbank, CA: ComPendium, LLC. https://www.emrap.org/corependium/chapter/recCvtWt5In5h4fLJ/Procedural-Sedation#h.9du7441ga4gn. Updated September 15, 2021. Accessed May 13, 2023.
  21. Midazolam. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  22. Fentanyl. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  23. Propofol. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  24. Etomidate. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  25. Ketamine. In: Lexicomp. UpToDate Inc; 2023. Accessed May 10, 2023. http://online.lexi.com
  26. Tagliafico L, Maizza G, Ottaviani S, et al. Pain in non-communicative older adults beyond dementia: a narrative review. Front Med (Lausanne). 2024;11:1393367. PublishedAugust 15, 2024. doi:10.3389/fmed.2024.1393367

FOAM and Further Reading

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Epilepsy and Status Epilepticus (2024)

by Rand Redwan Al Sari & Imad Khojah

You have a new patient!

A 22-year-old woman is brought to the ER because of violent, jerky movements of her limbs that started 30 minutes ago. Her husband reports that the patient has a history of epilepsy. She is unresponsive. Her examination reveals tonic-clonic episodes and blood in her mouth. How would you manage this case? What are the initial steps you would take? What actions are needed to stop the seizure?

a-photo-of-a-22-year-old-female-patient-with-seizure (the image was produced by using ideogram 2.0)

What do you need to know?

Epidemiology and Importance

Epilepsy is one of the most common neurological diseases that can present to the emergency department [1]. It affects about 50 million people around the world, with an incidence of approximately 50.4 to 81.7 per 100,000 per year [1]. Epilepsy refers to having a lower seizure threshold than normal due to genetic, pathological, or unknown causes [2]. It is characterized by recurrent unprovoked seizures that present with motor, sensory, autonomic, or cognitive function alterations [2]. Previously diagnosed patients can present to the ED with breakthrough seizures due to factors like changes in the anti-seizure regimen or noncompliance with medication [2]. Other factors like sleep deprivation, stress, and flashing lights can also precipitate breakthrough seizures [2].

Prolonged or repetitive uncontrollable seizures are termed status epilepticus [2,3]. This emergency requires prompt treatment to prevent neuronal injury, severe disability, coma, or death [3]. The overall case fatality rates can reach up to 15% [2].

Pathophysiology

Neurons are normally stabilized by a balance between excitatory and inhibitory neurotransmitters [2]. A disruption of this balance leads to abnormal electrical discharge [2]. This discharge can propagate to nearby areas in the brain, which is evident clinically by the stepwise spread of the seizure (known as Jacksonian March) [2, 4]. Loss of consciousness in some cases is explained by the widespread involvement of large areas of the brain [2]. Many drugs used to restore this balance work by enhancing inhibitory activity through targeting GABAA subtype receptors [2]. Prolongation of the seizure leads to sequestration of GABAA receptors and upregulation of excitatory receptors; therefore, patients become unresponsive to medication [2, 5]. This explains the importance of timely treatment through early seizure control to prevent morbidity and mortality in patients with status epilepticus [2,3].

Medical History

A common scenario presenting to the ER is a patient complaining of a seizure-like episode with a sudden loss of consciousness and motor activity involvement [6]. However, various other presentations of seizures and other differential diagnoses with similar complaints should not be neglected. If the patient presents with status epilepticus, timely management, depending on the seizure type, is urgently needed (see management) [2].

Through history and examination, distinguishing a seizure from other acute medical conditions is important. An accurate diagnosis has crucial, direct consequences for activity restriction and therapy planning. Paying attention to features, especially at the onset, can help in identifying the seizure type for therapeutic implications and facilitate communication between physicians. Semiology at onset is important to classify seizures as focal, focal with impaired awareness (complex seizures), generalized, or unknown [7]. Further classification divides motor and non-motor seizures based on the descriptive assessment of the first symptom, which can vary widely according to the area of the brain affected [2].

The main aim of history-taking is to identify seizures from other similar conditions, classify them, identify triggers of new seizures, and detect a cause for a decreased seizure threshold in a patient previously diagnosed with epilepsy [8].

It is important for any patient with seizures to consider critical causes such as eclampsia, toxic ingestion, hypoglycemia, electrolyte imbalance, and increased intracranial pressure [9]. Emergent diagnoses, such as infection, acute brain injury, and serious mimics of seizure activity, must be identified and treated as soon as possible [2].

Initial history approach to a patient with suspected seizure [2] is a systematic evaluation, starting with the assessment of whether the event is likely to be a seizure, followed by differentiation of first-time versus recurrent seizures, and identifying factors that may trigger or reduce seizure thresholds [10].

Algorithmic Approach in Seizure History [2]

Determining Likelihood of a Seizure

The process begins by evaluating whether the event could be a seizure. Key indicators include:

  • Aura: A subjective sensation preceding the seizure.
  • Abrupt onset: Sudden occurrence of the event.
  • Non-suppressible limb shaking: Movements that are not voluntary or suppressible.
  • Postictal state: A transient neurological state after the event, characterized by confusion or fatigue.
  • History of epilepsy: Previous diagnosis or known history can strongly support the likelihood.

If these features are absent, the clinician is prompted to consider alternative diagnoses, such as:

  • Syncope (fainting),
  • Stroke,
  • Complex migraine, or
  • Non-epileptic spells, which may mimic seizures but lack neurological underpinnings.

Differentiating First-Time Seizures

If the event is determined to likely be a seizure, the next step is assessing whether it is the patient’s first seizure. For first-time events, the focus shifts to identifying potential triggers, including:

  • Medications: Use of or withdrawal from drugs that may lower the seizure threshold.
  • Exposures: Environmental or toxicological factors.
  • Immunosuppression: Conditions that may predispose to infections affecting the brain.
  • History of head trauma: A common precipitant for seizures.
  • Pregnancy: Associated risks like eclampsia.

Characterization of the Seizure

If it is not a first-time seizure, further characterization of the event is essential. Key aspects include:

  • Onset: Understanding preceding events to identify immediate triggers and auras.
  • Duration: Length of the seizure episode.
  • Awareness: Assessing the patient’s level of consciousness during the seizure.
  • Automatisms: Involuntary, purposeless movements that occur during the seizure and can be observed by others.
  • Postictal state: The presence of transient neurological deficits following the seizure (absent in some types, such as absence seizures).

The clinician also verifies whether the current event is consistent with the patient’s previous seizure patterns.

Exploring Factors Reducing the Seizure Threshold

For patients with recurrent seizures, it is crucial to evaluate factors that might decrease the seizure threshold, including:

  • Non-compliance or changes to anti-seizure drug (ASD) regimens.
  • Illness or trauma: Physical or psychological stressors.
  • Drug or alcohol use: Acute intoxication or withdrawal.
  • Catamenial exacerbations: Hormonal influences in menstruating individuals.
  • Pregnancy: Increased risk of seizures due to physiological changes or complications.
  • Sleep deprivation: A well-documented precipitant of seizures.

This step ensures that modifiable triggers or exacerbating factors are identified and addressed.

Physical Examination

Physical examination is crucial for identifying etiologies and directing the management plan. During an active seizure, pay close attention to posture, motor activity, eye deviation, and nystagmus, observing asymmetries and focal findings [11]. Check if the clonic activity is suppressible by applying gentle pressure. Unlike insuppressible seizures, suppression suggests a different diagnosis, such as nonepileptic spells or movement disorders. Check for mydriasis in the eyes, which is commonly found during seizures, but its persistence afterward can indicate toxic exposure [2].

Vital signs should be measured after seizure activity has ceased. They are of high importance and may direct the physician to possible causes (e.g., fever suggests meningoencephalitis, tachycardia and hypertension suggest toxic sympathomimetic exposure, while hypertension and bradycardia can indicate herniation syndromes) [2].

Moreover, a general examination should aim to search for both findings and sequelae of the seizures. Physical findings such as nuchal rigidity, stigmata of substance abuse, and lymphadenopathy may be present. Potential sequelae of seizures should also be assessed [12]. Evaluation of soft tissue and skeletal trauma is important, as injuries are common. Check for head trauma, tongue injury, shoulder dislocation, bone fractures, or aspiration [2].

Finally, a complete neurological examination should be performed. Immediately following the seizure, hyperreflexia, focal motor deficit (Todd’s paralysis), and extensor plantar response (positive Babinski) can occur and are expected to generally resolve within an hour [13]. If Todd’s paralysis does not resolve quickly, it raises the suspicion of a focal structural deficit that caused the seizure (e.g., stroke). The persistence of altered consciousness or signs of ongoing subtle seizures, such as automatisms, abnormal eye movements, and facial myoclonus, suggests the persistence of the seizure and must not be missed (nonconvulsive seizures and status epilepticus) [2].

Alternative Diagnoses

Although no single clinical finding or diagnostic modality is 100% confirmatory of the diagnosis of seizures [14, 15], understanding the circumstances of the event and the factors surrounding it can help rule out or confirm diagnoses with similar presentations [2].

Findings that make the diagnosis of seizures more probable include postictal disorientation and amnesia, cyanosis during the event, lateral tongue biting, non-suppressible limb shaking, and dystonic posturing [2, 15].

If the patient experienced diaphoresis, palpitations, nausea, and vomiting before the seizure, it may suggest transient cerebral ischemia due to arrhythmias [2].

The presence of motor activity, commonly including a tonic extension of the trunk or myoclonic jerks of the extremities associated with bradycardia, raises the suspicion of convulsive syncope [16]. Once cerebral perfusion is restored, convulsions stop without any postictal period [2].

The diagnosis of migraine can sometimes be misleading due to the presence of a preceding aura that might be confused with nonconvulsive seizures (e.g., the positive visual phenomenon in occipital seizures) [17]. Unlike occipital seizures, migraines have a peak preceded by gradual evolution and followed by gradual resolution. Moreover, patients typically have a positive history of migraines with a similar presentation [2].

Nonepileptic spells or psychogenic seizures mimic status epilepticus in their presentation [18]. Due to the prolonged duration of the spells (five minutes or more, and sometimes exceeding 20 minutes), patients commonly receive high doses of benzodiazepines and need to be monitored for any respiratory compromise. Findings consistent with this diagnosis include a stop-and-go pattern of the convulsions, horizontal head shaking, forward pelvic thrusting, asynchronous bilateral convulsions with eyes closed, a short postictal period despite the long duration of spells, avoidance of noxious stimuli, and preserved recollection of events. Furthermore, laboratory testing lacks reactive leukocytosis and lactic acidosis, which are present in nearly all cases of prolonged generalized convulsive seizures or status epilepticus [2, 19].

Acing Diagnostic Testing

Due to the challenges of diagnosing a seizure, seeking diagnostic testing is of high value. Laboratory studies, radiology, and other special procedures frequently provide important elements in patient assessment [20]. Although some cases require extensive metabolic testing, it is not indicated for cases with an unremarkable history and normal examination findings. Serum glucose levels should be measured in all cases, as hypoglycemia is a common cause of provoked seizures [21]. It is also important to note that hypoglycemia could result from prolonged seizures. If correcting the glucose level does not stop a seizure, an alternate diagnosis should be evaluated. Lactic acid and creatinine kinase should also be measured in cases of prolonged seizures to assess for acute metabolic acidosis and rhabdomyolysis, respectively [22]. A low level of lactic acid during a prolonged convulsive episode makes a seizure less likely (nonepileptic convulsions) [2].

On the other hand, the presence of advanced age, comorbidities, abnormal examination findings, or an ill appearance demands comprehensive metabolic testing. Such testing includes serum glucose, creatinine kinase, lactic acid, electrolytes, complete blood count, urea nitrogen, creatinine, AST, ALT, anti-seizure drug levels, pregnancy tests, and drug-of-abuse screening. Checking for electrolyte derangements is important, as these can trigger seizures (e.g., hyponatremia, hypocalcemia, and hypomagnesemia) [23]. Patients with a low bicarbonate level should undergo blood gas analysis. An anion gap metabolic acidosis resulting from lactic acidosis is expected to decline within the first hour after the convulsive seizure stops unless another cause is present. Liver enzymes are tested to check for liver-mediated metabolic abnormalities that can impact therapeutic decisions [2].

Furthermore, patients on antiseizure medication should have their levels checked to confirm compliance. Some drugs are known to be epileptogenic, and it may be necessary to test their levels as well. Drug-of-abuse screening can also be considered in patients presenting with first-time seizures, despite the fact that such testing cannot prove causation or change outcomes [2, 24].

Urgent neuroimaging is indicated for most cases of a first-time seizure, whereas patients with epilepsy who have returned to baseline do not require one. Prompt neuroimaging and CT consideration in the ER is indicated for patients with coma, focal neurological deficits, immunocompromised states, advanced age, anticoagulation use, malignancy, previous intracranial hemorrhage, severe thunderclap headache, status epilepticus, neurocutaneous syndromes, or suspected trauma [25]. Computed tomography (CT) is widely available, but MRI and CT perfusion can provide additional information. If an infection is suspected, lumbar puncture is indicated [2].

Electroencephalography (EEG) is useful for diagnosing nonconvulsive seizures, epilepsy, nonepileptic spells, and status epilepticus [26]. EEG can guide therapy and monitor the treatment of refractory cases. Although it is not cost-effective, it is a high-yield modality for cases with an unclear diagnosis [2].

Lastly, ECG monitoring might benefit patients with preceding or ongoing cardiac symptoms. It can provide early clues in cases of drug toxicity and help understand the etiology of the seizure [2, 27].

Risk Stratification

The presentation and findings of a seizure case can provide clues as to whether this case has any red flags that demand urgent care. History and examination findings such as immunocompromisation, the presence of a thunderclap headache, sudden neurological deficit, status epilepticus presentation, head trauma, persistent altered consciousness, and concurrent infection can indicate a worse outcome [10]. Such patients require extensive investigations and prompt treatment to minimize morbidity and mortality due to the cause of the seizure or as a consequence of the seizures themselves [28]. Critical care for these patient groups is essential to reduce complications such as infection-related issues, irreversible intracranial structural disease, refractory status epilepticus, hemodynamic compromise, and death [2].

The risks of experiencing a secondary seizure following the current presentation may change the management plan to include secondary seizure prophylaxis. Risk stratification, weighing the chances of recurrence (higher in patients with previous brain insult, abnormal EEG, brain imaging abnormalities, and the presence of nocturnal seizures) against the risks of adverse effects from antiseizure medication, should be conducted in collaboration with a consulting neurologist [2].

Management

The initial priorities in managing unstable patients are to recognize and treat hypoxia, hypotension, and hypoglycemia, and to initiate pharmacologic treatment when needed [2, 28, 29].

Initial stabilization of patients with active seizures presenting to the ER includes the following [2, 28, 29]:

  • Assess airway, breathing, and circulation: Do not use nasopharyngeal airway devices during the seizure, as they can cause injury and increase the risk of aspiration.
  • Pulse oximetry.
  • Electrocardiogram (ECG).
  • Finger stick: If the glucose level is less than 60 mg/dL, administer IV dextrose.
  • Aspiration precaution: Place the patient in the lateral decubitus position.
  • Abortive treatment: Administer if the seizure lasts more than 5 minutes or in the case of hemodynamic compromise.

First-line therapy [2, 28, 29]

The first-line pharmacological therapies for managing epilepsy, include three benzodiazepine agents: diazepam, lorazepam, and midazolam. These agents are commonly used for their rapid onset and efficacy in controlling seizures, especially status epilepticus. The table includes critical details on dosing, frequency, maximum permissible dose, pregnancy category, and specific cautions.

  1. Diazepam
  • Dose per kilogram: 0.15-0.2 mg/kg intravenously (IV).
  • Frequency: Administered every 5 minutes as needed.
  • Maximum Dose: Limited to 10 mg per individual dose and a cumulative total of 30 mg across all doses.
  • Pregnancy Category: D (indicating a potential risk to the fetus, but benefits may outweigh risks in life-threatening situations).
  • Cautions/Comments:
    • Continuous monitoring of respiration is essential due to the risk of respiratory depression, a common side effect of benzodiazepines.
  1. Lorazepam
  • Dose per kilogram: 0.1 mg/kg intravenously (IV).
  • Frequency: Administered every 5 minutes as necessary.
  • Maximum Dose: 4 mg per dose, with a cumulative maximum of 12 mg across all doses.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Similar to diazepam, respiratory monitoring is mandatory.
    • Intramuscular (IM) administration is contraindicated for lorazepam, likely due to inconsistent absorption or slower onset compared to IV administration.
  1. Midazolam
  • Dose per kilogram: 0.2 mg/kg, administered via multiple routes including IV, intramuscular (IM), or intranasal (IN).
  • Frequency: Doses can be repeated every 5 minutes as needed.
  • Maximum Dose: 10 mg per individual dose.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Respiratory monitoring is critical due to the sedative effects of midazolam.
    • The half-life of midazolam is approximately 7 hours, making it a relatively short-acting agent compared to others, which can influence its clinical use depending on seizure recurrence risk.

All three agents are effective for rapid seizure control but share common risks, including respiratory depression, necessitating vigilant monitoring, particularly in critical care or emergency settings. Their classification in pregnancy category D highlights the need for careful consideration of maternal and fetal risks versus benefits. Midazolam offers more flexibility in administration routes, making it a practical choice in situations where IV access is not readily available.

If the seizure stops, coordinate a disposition plan and consider non-convulsive status epilepticus in patients who do not return to baseline. However, if the seizure does not stop, ensure adequate dosing of first-line therapy, then proceed to second-line therapy, and finally to third-line therapy, one step at a time [2, 28, 29].

Second-line therapy [2, 28, 29]

The second-line treatment options for epilepsy, include on a variety of antiepileptic drugs. These agents are typically used when first-line benzodiazepines are insufficient to control seizures. The table details dosing, frequency, maximum permissible doses, pregnancy categories, and relevant cautions for clinical use.

  1. Levetiracetam
  • Dose per kilogram: 40-60 mg/kg administered intravenously (IV).
  • Frequency: Administered once over a 10-minute period.
  • Maximum Dose: 4500 mg.
  • Pregnancy Category: C (indicating that risks cannot be ruled out, but the drug may be used if benefits outweigh potential risks).
  • Cautions/Comments:
    • Requires renal clearance, so dose adjustments may be necessary in patients with renal impairment.
  1. Fosphenytoin
  • Dose per kilogram: 10-20 mg PE/kg (phenytoin equivalents) given IV or intramuscularly (IM).
  • Frequency: Additional 5 mg PE/kg can be administered after 10 minutes if needed.
  • Maximum Dose: 150 mg PE/kg.
  • Pregnancy Category: D (associated with risk but can be used in life-threatening situations).
  • Cautions/Comments:
    • Can cause hypotension and dysrhythmias, requiring cardiac monitoring during administration.
  1. Lacosamide
  • Dose per kilogram: 200-400 mg IV.
  • Frequency: An additional 5 mg/kg can be administered if necessary.
  • Maximum Dose: 250 mg.
  • Pregnancy Category: C.
  • Cautions/Comments:
    • Can cause arrhythmias.
    • Renal clearance is required, so adjustments are needed for patients with renal insufficiency.
  1. Phenobarbital
  • Dose per kilogram: 15-20 mg/kg IV.
  • Frequency: Additional 5-10 mg/kg can be given as needed.
  • Maximum Dose: Not explicitly mentioned but calculated based on repeated doses.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Monitor respiration closely due to the sedative and respiratory depressant effects.
    • A strong P450 enzyme inducer, which can affect the metabolism of other drugs.
  1. Phenytoin
  • Dose per kilogram: 15-20 mg/kg IV.
  • Frequency: Additional 5-10 mg/kg can be administered if necessary.
  • Maximum Dose: 30 mg/kg.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Risk of hypotension and dysrhythmias during administration, necessitating monitoring.
    • A strong P450 enzyme inducer, which impacts the metabolism of other medications.
  1. Valproic Acid
  • Dose per kilogram: 20-40 mg/kg IV.
  • Frequency: Additional doses of 20 mg/kg can be administered if necessary.
  • Maximum Dose: 3000 mg.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Strong P450 enzyme inducer.
    • May cause hepatotoxicity and platelet dysfunction, warranting caution in patients with liver disease or coagulopathy.

The second-line agents are reserved for scenarios where first-line therapy fails to achieve seizure control. Each agent has specific risks and monitoring requirements. For example:

  • Levetiracetam and lacosamide are generally well-tolerated but require dose adjustments in renal impairment.
  • Phenobarbital, phenytoin, and valproic acid necessitate respiratory and hepatic monitoring due to their systemic side effects.
  • Fosphenytoin and phenytoin require cardiac monitoring due to their potential to induce arrhythmias.

The choice of agent depends on the patient’s clinical status, underlying conditions, and the safety profile of the drug.

Third-line therapy [2, 28, 29]

The third-line therapy agents for managing refractory epilepsy, particularly in patients requiring intubation, mechanical ventilation, and hemodynamic support are administered in critical care settings to control seizures when first- and second-line therapies fail. Each drug is described with its dosing regimen, frequency, maximum dose, pregnancy category, and significant precautions.

  1. Ketamine
  • Dose per kilogram:
    • Loading dose: 1.5 mg/kg intravenously (IV).
    • Maintenance dose: 0.5 mg/kg every 3-5 minutes as needed.
  • Maximum Dose: Not explicitly stated, but administered as required to control seizures.
  • Pregnancy Category: N (Not classified).
  • Cautions/Comments:
    • Ketamine acts as an NMDA antagonist, a unique mechanism among anticonvulsants.
    • Hypotension is a potential side effect, necessitating blood pressure monitoring.
  1. Midazolam
  • Dose per kilogram:
    • Loading dose: 0.2 mg/kg IV.
    • Maintenance dose: 0.2-0.4 mg/kg every 3-5 minutes.
  • Maximum Dose: 2 mg/kg for the loading dose.
  • Pregnancy Category: D (Risk to the fetus exists, but use may be justified in emergencies).
  • Cautions/Comments:
    • Midazolam may cause hypotension and requires continuous hemodynamic monitoring.
  1. Pentobarbital
  • Dose per kilogram:
    • Loading dose: 5-15 mg/kg IV.
    • Additional doses of 5-10 mg/kg may be given if required.
  • Maximum Dose: 25 mg/kg for the loading dose.
  • Pregnancy Category: D.
  • Cautions/Comments:
    • Pentobarbital has a long half-life (22 hours), which makes it effective for sustained seizure control but may prolong sedation.
    • It carries significant risks, including hypotension, ileus, myocardial suppression, immunosuppression, and thrombocytopenia, requiring vigilant monitoring in an intensive care setting.
  1. Propofol Infusion
  • Dose per kilogram:
    • Loading dose: 1-2 mg/kg IV.
    • Maintenance dose: 0.5-2 mg/kg every 3-5 minutes as needed.
  • Maximum Dose: 10 mg/kg for the loading dose.
  • Pregnancy Category: B (Lower risk, but use must be cautious).
  • Cautions/Comments:
    • Propofol has a short half-life (0.6 hours), allowing for rapid onset and recovery.
    • Side effects include hypotension, respiratory depression, hypertriglyceridemia, pancreatitis, and the rare but potentially fatal propofol infusion syndrome. Close monitoring of triglycerides and cardiac function is necessary.

Third-line therapies are used in severe, refractory cases of epilepsy where intubation, ventilation, and hemodynamic support are required. These drugs induce deep sedation or anesthesia to suppress seizure activity effectively. Key considerations for their use include:

  • Ketamine: Offers a unique mechanism (NMDA antagonism), useful in resistant cases.
  • Midazolam and pentobarbital: Provide effective sedation but require careful respiratory and cardiovascular monitoring due to risks of hypotension and prolonged sedation.
  • Propofol: Its short duration of action allows for precise titration, but metabolic side effects and infusion syndrome necessitate caution.

The choice of agent depends on the clinical scenario, patient stability, and institutional protocols. These medications are used alongside comprehensive critical care support to manage complications and optimize outcomes.

Special Patient Groups

Certain notes are important to remember regarding special patient groups. In cases of seizures during pregnancy, considering the diagnosis of eclampsia is a high priority. Magnesium is the drug of choice for acute eclamptic seizures [30]. If a pregnant patient was previously diagnosed with epilepsy, a lower seizure threshold may result due to noncompliance, adjusted regimens, sleep deprivation, nausea and vomiting, or increased drug clearance. When managing status epilepticus, the risks to the fetus from the seizure are higher than the risks from the medication; therefore, manage the patient as you would a nonpregnant individual [31]. In the case of a new, non-eclamptic seizure, a workup is indicated as previously mentioned [2].

When To Admit This Patient

The decision to admit or discharge should be individualized based on the underlying illness, recurrence risk, and need for maintenance pharmacotherapy [32]. Admission for observation alongside neurological consultation should be considered for patients with an uncertain diagnosis, a history of neurological disease or other comorbidities, or in situations where follow-up is unlikely. In contrast, patients can be discharged home with early referral to a neurologist if they have normal examination findings, no significant comorbidities, no known structural brain disease, did not require more than a single dose of benzodiazepines, and are expected to comply with follow-up instructions [2].

Discharge instructions should include guidance on car driving, potentially dangerous activities (e.g., swimming, cycling, climbing ladders), and information regarding any needed follow-up [2, 33].

Revisiting Your Patient

A 22-year-old woman with a previous history of epilepsy was brought to the ER due to generalized tonic-clonic insuppressible movements of her limbs that started 15 minutes ago.

You immediately assessed the airway, breathing, and circulation and placed the patient in the lateral decubitus position to prevent aspiration, as she had a tongue injury. Blood sugar was measured using a finger stick, ruling out hypoglycemia. Lorazepam was then administered as abortive treatment.

You began taking a history from her husband. They were having lunch together when his wife suddenly started seizing, and he was unable to stop it. She had not regained consciousness since then. He mentioned that she had been inconsistent with her antiepileptic medication because she wanted to get pregnant and had read online about potential harms of the medications on a growing baby.

Her lactic acid level was high, her pregnancy test was negative, and the rest of her laboratory findings were within normal limits.

The patient was diagnosed with status epilepticus, a medical emergency requiring urgent management. The ABC approach was performed to ensure the patient’s safety, followed by the administration of benzodiazepines. If first-line therapy fails, second- and third-line therapies should be administered sequentially. Inconsistency with antiepileptic medication highlights the need for patient education and further discussion regarding her concerns and available treatment options.

Authors

Picture of Rand Redwan Al Sari

Rand Redwan Al Sari

Dr Rand Al Sari is a dedicated General Physician practicing in Saudi Arabia. With a strong commitment to patient care, she is also actively engaged in medical research, staying at the forefront of healthcare advancements and integrating this knowledge into her clinical practice. Passionate about medical writing and journaling, Dr Al Sari reflects on her experiences to contribute meaningfully to the medical community, with a focus on evidence-based healthcare and improving patient outcomes.

Picture of Imad Khojah

Imad Khojah

Listen to the chapter

References

  1. Falco-Walter, Jessica. Epilepsy—definition, classification, pathophysiology, and epidemiology. Thieme Medical Publishers. 2020; 40(6): 617-623.
  2. John A. Ron M, et al. Rosen’s Emergency Medicine: Concepts and Clinical Practice. Philadelphia: Elsevier; c2014: 156-161, 1375-1385.
  3. Migdady I, Rosenthal ES, Cock HR. Management of status epilepticus: a narrative review. Wiley online library. 2022; 77:78-91.
  4. Extercatte J, de Haan GJ, Gaitatzis A. Teaching Video NeuroImages: Frontal opercular seizures with jacksonian march. Neurology. 2015;84(11):e83-e84. doi:10.1212/WNL.0000000000001363
  5. Casasola C, Montiel T, Calixto E, Brailowsky S. Hyperexcitability induced by GABA withdrawal facilitates hippocampal long-term potentiation. Neuroscience. 2004;126(1):163-171. doi:10.1016/j.neuroscience.2004.03.029
  6. Williams J, Doherty J, Di Blasi C, Mabarak D, Kennedy U, Doherty CP. Seizure care in the emergency department. Identifying and bridging the gaps. A study of care and outcomes from 644 seizure presentations. Epilepsy Behav. 2018;78:226-231. doi:10.1016/j.yebeh.2017.08.042
  7. Jan MM, Girvin JP. Seizure semiology: value in identifying seizure origin. Can J Neurol Sci. 2008;35(1):22-30. doi:10.1017/s0317167100007526
  8. Benton TJ, Narayanan D. Differentiating seizure and convulsive syncope: the importance of history taking. Postgrad Med. 2008;120(1):50-53. doi:10.3810/pgm.2008.04.1760
  9. Luft, Andreas. (2005). Critical Care Seizures Related to Illicit Drugs and Toxins. 10.1007/978-1-59259-841-0_13.
  10. Mantoan L, Kullmann DM. Evaluating first seizures in adults in primary care. Practitioner. 2011;255(1743):25-3.
  11. García-Pastor A, López-Esteban P, Peraita-Adrados R. Epileptic nystagmus: a case study video-EEG correlation. Epileptic Disord. 2002;4(1):23-28.
  12. Lee WL. Long-term sequelae of epilepsy. Ann Acad Med Singap. 1989;18(1):49-51.
  13. Xu SY, Li ZX, Wu XW, Li L, Li CX. Frequency and Pathophysiology of Post-Seizure Todd’s Paralysis. Med Sci Monit. 2020;26:e920751. Published 2020 Mar 5. doi:10.12659/MSM.920751
  14. Angus-Leppan H. Diagnosing epilepsy in neurology clinics: a prospective study. Seizure. 2008;17(5):431-436. doi:10.1016/j.seizure.2007.12.010
  15. Benbadis S. The differential diagnosis of epilepsy: a critical review. Epilepsy Behav. 2009;15(1):15-21. doi:10.1016/j.yebeh.2009.02.024
  16. Doležalová I, Brázdil M, Rektor I, Tyrlíková I, Kuba R. Syncope with atypical trunk convulsions in a patient with malignant arrhythmia. Epileptic Disord. 2013;15(2):171-174. doi:10.1684/epd.2013.0564
  17. Schulze-Bonhage A. Visuelle Aura: Differenzialdiagnose zwischen Migräne und Epilepsie [Differential diagnosis of visual aura in migraine and epilepsy]. Klin Monbl Augenheilkd. 2001;218(9):595-602. doi:10.1055/s-2001-17636
  18. Krebs PP. Psychogenic nonepileptic seizures. Am J Electroneurodiagnostic Technol. 2007;47(1):20-28.
  19. van Rooij FJ, Admiraal-van de Pas Y. Lactaatacidose in de postictale fase [Lactic acidosis in the postictal state]. Ned Tijdschr Geneeskd. 2015;159:A9068.
  20. Valeta, Thalia. (2017). Investigations for Epileptic Seizures. 10.1007/978-3-319-61679-7_14.
  21. Nuoffer JM, Mullis PE. Hypoglykämien–Diagnostik und Therapie im Notfall [Hypoglycaemia–diagnosis and therapy in emergencies]. Ther Umsch. 2005;62(8):543-548. doi:10.1024/0040-5930.62.8.543
  22. Nass RD, Sassen R, Elger CE, Surges R. The role of postictal laboratory blood analyses in the diagnosis and prognosis of seizures. Seizure. 2017;47:51-65. doi:10.1016/j.seizure.2017.02.013
  23. Castilla-Guerra L, del Carmen Fernández-Moreno M, López-Chozas JM, Fernández-Bolaños R. Electrolytes disturbances and seizures. Epilepsia. 2006;47(12):1990-1998. doi:10.1111/j.1528-1167.2006.00861.x
  24. Ng SK, Brust JC, Hauser WA, Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol. 1990;132(1):47-57. doi:10.1093/oxfordjournals.aje.a115642
  25. Rittenberger JC. Early CT imaging of the brain – A guide to therapy. Resuscitation, 2014;85(10):1309-1310. doi: 10.1016/J.RESUSCITATION.2014.06.020
  26. Rosenow F, Klein KM, Hamer HM. Non-invasive EEG evaluation in epilepsy diagnosis. Expert Rev Neurother. 2015;15(4):425-444. doi:10.1586/14737175.2015.1025382
  27. Ufongene C, El Atrache R, Loddenkemper T, Meisel C. Electrocardiographic changes associated with epilepsy beyond heart rate and their utilization in future seizure detection and forecasting methods. Clin Neurophysiol. 2020;131(4):866-879. doi:10.1016/j.clinph.2020.01.007
  28. Bank AM, Bazil CW. Emergency Management of Epilepsy and Seizures. Semin Neurol. 2019;39(1):73-81. doi:10.1055/s-0038-1677008
  29. Huff JS, Morris DL, Kothari RU, Gibbs MA; Emergency Medicine Seizure Study Group. Emergency department management of patients with seizures: a multicenter study. Acad Emerg Med. 2001;8(6):622-628. doi:10.1111/j.1553-2712.2001.tb00175.x
  30. Keepanasseril A, Maurya DK, Manikandan K, Suriya J Y, Habeebullah S, Raghavan SS. Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: randomised controlled trial (PIPES trial). J Obstet Gynaecol. 2018;38(3):305-309. doi:10.1080/01443615.2017.1351931
  31. Thomas SV. Management of epilepsy and pregnancy. J Postgrad Med. 2006;52(1):57-64.
  32. Agarwal P, Xi H, Jette N, et al. A nationally representative study on discharge against medical advice among those living with epilepsy. Seizure. 2021;84:84-90. doi:10.1016/j.seizure.2020.11.018
  33. Engel KG et al. Patient comprehension of emergency department care and instructions: Are patients aware of when they do not understand? Ann Emerg Med2009 Apr; 53:454.

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Antidotes (2024)

by Sarah Alzaabi

Introduction

An antidote is a specific agent designed to counteract the toxic effects caused by drugs or poisons [1]. These substances play a crucial role in toxicology, as they can effectively mitigate or reverse the harmful consequences of various toxic exposures. In clinical practice, the availability of antidotes is somewhat limited, with only a select number approved for use depending on the type of toxin involved [2].

It’s important to note that antidotes are not administered indiscriminately; instead, they are used based on clearly defined clinical guidelines. Each antidote has specific indications that dictate when it should be given, ensuring that patients receive the appropriate treatment in situations of toxicity. Proper identification of the toxin and the clinical scenario is essential to determine the need for an antidote and to maximize its therapeutic efficacy.

Many poisons have no true antidote, and the poison(s) involved may initially be unknown [3, 4]. Furthermore, limiting the differential diagnosis to poisoning can deter the identification of other pathologies that may exist in these patients [3, 4]. Therefore, the initial approach should be to assess and stabilize [4, 5] thoroughly. Similar to any compromised patient, the attention is directed toward securing the airway, breathing, circulation, and decontamination [4, 5]. There are only a few indications where antidotes are prioritized over cardiopulmonary stabilization, i.e., naloxone for opioid toxicity, cyanide antidotes for cyanide toxicity, and atropine for organophosphate poisoning [5]. Otherwise, most patients will have good outcomes with supportive management and a period of observation [1, 3, 4, 5].

Administration of pharmacologic antagonists may worsen the outcome in some situations and is not recommended [2, 3]. Therefore, the physician should know the indications and contraindications of each antidote [2, 3]. When in doubt, consult a poison control center or a medical or clinical toxicologist [2, 4].
In summary, it’s important to understand that antidotes should be utilized as complementary treatments rather than the sole focus in managing poisoning cases [1]. The primary objective should always be to address the patient’s overall condition, taking into account their symptoms and needs, rather than concentrating exclusively on the specific toxin involved [4]. This approach ensures a more comprehensive and effective care strategy for individuals affected by poisoning.

Pregnant Patients and Antidotes

Limited data is available on the use of antidotes in pregnancy [4]. Hence, the teratogenic potential of antidotes is not fully understood [7]. The general initial management principles are the same, and stabilization of the mother is the priority [6].

The risks and benefits of using or withholding antidotes must be assessed. In general, antidotes are not used for uncertain indications, but proven effective treatments should not be withheld from the mother based on theoretical danger to the fetus [4].

There is no known indication for fetal antidote therapy [7]. However, if an antidote is to be given for fetal benefit, it should be done rapidly in the acute setting [7]. This specifically applies to chelators such as dimercaprol, calcium EDTA, and deferoxamine, which will prevent the toxin from passing into fetal circulation [7].

The following section presents information about various antidotes, organized in alphabetical order.

Antidotes

Atropine

General Information

  • Anticholinergic agent, competitive muscarinic antagonist [3, 4, 5, 8].

Indications

  • Organophosphate poisoning, carbamates, nerve agents [3, 4, 5, 8].

Precautions

  • Excessive doses may cause anticholinergic symptoms [5].

Dose/Administration

  • Adults: Start with 1-2 mg IV, double the dose every 2-3 minutes to reach the goal [3, 4, 5, 8].
  • Children: 0.02 mg/kg IV (minimum of 0.1 mg) [3].

Other Notes

  • Large doses may be required.
  • Goal: Drying of respiratory secretions/improved work of breathing [3, 8].
  • Tachycardia is not the endpoint (atropine helps with muscarinic effects; pralidoxime is used for nicotinic effects) [3, 8].

Calcium

General Information

  • Calcium chloride 10% (1 g/10 mL, 27.2 mg/mL elemental Ca).
  • Calcium gluconate 10% (9 mg/mL elemental Ca), one-third strength of calcium chloride [5].

Indications

  • Calcium channel blocker toxicity, hydrofluoric acid exposure, hyperkalemia, hypermagnesemia [4, 5, 9].

Precautions

  • Calcium chloride extravasation can cause soft tissue necrosis; prefer central line administration [9].
  • Continuous monitoring is recommended [9].

Dose/Administration

  • Adults:
    • Calcium chloride: 0.5-1 g IV (5-10 mL) [5, 9].
    • Calcium gluconate: 1-3 g IV (10-30 mL) [5].
  • Children: 0.15 mL/kg calcium chloride IV [5].
  • IV bolus over 5-10 minutes; repeated doses every 10-20 minutes as needed, guided by serum Ca+ or QT interval [9].
  • Infusion available [9].

Other Notes

  • For HF acid skin burns: Topical 2.5% calcium gel or local injection of calcium gluconate [9].
  • Regional block with intra-arterial or IV calcium gluconate for extremity exposure [9].
  • Nebulized calcium gluconate for HF acid inhalation injury [9].

Cyproheptadine

General Information

  • Antihistaminic and antiserotonergic agent; also has anticholinergic activity [10].

Indications

  • Serotonin syndrome [4, 10].

Dose/Administration

  • Adults: 8 mg every 8 hours for 24 hours (if response observed) [10].
  • Children: 4 mg (not well established) [10].

Deferoxamine

General Information

  • Iron-chelating agent that converts iron to a water-soluble complex for renal clearance [3, 11].

Indications

  • Systemic iron toxicity (e.g., severe gastroenteritis, shock, metabolic acidosis, altered mental status) [3, 4, 11].
  • Iron levels >500 µg/dL or multiple pills on radiography [3, 4, 11].
  • Chronic iron overload [3, 4, 11].

Precautions

  • Hypotension may occur at rapid infusion rates; ensure adequate hydration [3].
  • Cardiac monitoring is needed [11].

Dose/Administration

  • Start with IV infusion: 15 mg/kg/h (maximum 1 g/h) over 6 hours; re-evaluate [3, 11].
  • Infusion rate can be increased in critical patients if blood pressure allows [11].

Other Notes

  • Urine may become rusty-red as iron is excreted [3, 11].

Digoxin Immune Fab

General Information

  • Fab fragments of antibodies to digoxin, reversing cardiotoxic effects [1, 3].

Indications

  • Digoxin overdose with potassium >5 mEq/L after acute ingestion, hemodynamic instability, or life-threatening dysrhythmias [3].
  • Poisoning by other cardiac glycosides (e.g., Oleander) [1, 3, 5, 12].

Precautions

  • Close monitoring of digoxin serum levels, vital signs, and ECG. Resuscitation equipment should be ready [12].

Dose/Administration

  • Acute overdose:
    • Stable patients: 5 vials.
    • Unstable patients: 10-20 vials [3, 5].
  • Chronic overdose: Start with 1-2 vials, repeat after 60 minutes if needed [12].
  • Calculate dose if the ingested dose is known (40 mg Fab binds 0.6 mg digoxin) [3, 5].
  • Bolus in life-threatening conditions (e.g., cardiac arrest) or infusion over 30 minutes, monitoring clinical response [3, 12].

Other Notes

  • For other cardiac glycoside poisoning: Start with 5 vials [3, 12].

Dimercaprol (BAL)

General Information

  • Heavy metal chelator [1, 14].

Indications

  • Severe lead, inorganic arsenic, and mercury poisoning [1, 4, 13].

Precautions

  • Severe adverse effects include nephrotoxicity; consider using EDTA or succimer instead if possible [13].

Dose/Administration

  • 3 mg/kg IM every 4 hours for 48 hours, then every 12 hours for 7-10 days based on clinical response [13].

Ethanol

General Information

  • Blocks formation of toxic metabolites of alcohols [14].

Indications

  • Methanol and ethylene glycol poisoning (second-line to fomepizole) [5, 14].

Precautions

  • Maintain blood ethanol concentration between 100-150 mg/dL [14].

Dose/Administration

  • IV:
    • Loading: 10 mL/kg of 10% ethanol.
    • Maintenance: 1-2 mL/kg/h of 10% ethanol [14].
  • Oral:
    • Loading: 1.8 mL/kg of 43% ethanol.
    • Maintenance: 0.2-0.4 mL/kg/hour of 43% ethanol [14].

Flumazenil

General Information

  • Competitive antagonist of GABA-benzodiazepine receptors [1, 2, 3, 15].

Indications

  • Benzodiazepine overdose (limited role), reversal of procedural sedation, accidental pediatric ingestion [1, 3, 5, 15].

Precautions

  • May cause withdrawal or seizures, especially in benzodiazepine dependence or mixed overdoses [2, 3, 15].

Dose/Administration

  • Adults: 0.2 mg IV over 30 seconds, repeat every minute until reversal (maximum 3 mg) [1, 3, 5, 15].
  • Children: 0.01-0.02 mg/kg, repeat every minute [1, 5, 15].

Other Notes

  • Limited role due to risk of seizures [1, 3, 15].

Fomepizole

General Information

  • Alcohol dehydrogenase inhibitor [1, 3, 16].

Indications

  • Methanol and ethylene glycol toxicity (first-line due to better side effect profile) [1, 3, 5, 16].

Dose/Administration

  • Loading dose: 15 mg/kg IV infusion in 100 mL normal saline or 5% dextrose over 30 minutes [1, 3, 16].
  • Maintenance dose: 10 mg/kg every 12 hours for 48 hours, then 15 mg/kg every 12 hours until alcohol concentrations <20 mg/dL [1, 16].
  • In dialyzed patients: Give every 4 hours or continuous infusion of 1 mg/kg/h [16].

Other Notes

  • Continue therapy until alcohol concentrations are <20 mg/dL and the patient is asymptomatic [3].

Glucagon

General Information

  • Increases cyclic AMP (cAMP).
  • Positive inotropic and chronotropic properties, similar to beta-agonists [18].

Indications

  • β-blocker toxicity (adjunct).
  • Calcium channel blocker toxicity [5, 17, 18].

Precautions

  • Induces vomiting; consider anti-emetics and airway management [18, 19].

Dose/Administration

  • Adults: 5-10 mg IV bolus over 1-2 minutes [5, 18, 19].
  • Children: 0.05-0.1 mg/kg IV [19].

Other Notes

  • If there is a clinical response, start an infusion [18].
  • Intravenous fluids, vasopressors, and high-dose insulin with dextrose are first-line treatments for β-blocker toxicity [19].

Hydroxocobalamin

General Information

  • Precursor of Vitamin B12 [20].

Indications

  • Cyanide toxicity (forms cyanocobalamin by displacing hydroxyl group) [3, 5, 20].

Precautions

  • Safe drug with low side effects.

Dose/Administration

  • Adults: 5 g in 100 mL normal saline IV infusion over 15 minutes; repeat if needed [3, 5, 20].
  • Children: 70 mg/kg IV over 15 minutes (maximum 5 g) [3, 5].

Other Notes

  • Causes orange-red discoloration of skin and urine, resolving within 24-48 hours [3].

Insulin (High Dose)

General Information

  • Strong inotropic effects [21].

Indications

  • Calcium channel blocker and β-blocker toxicity [5, 21].

Precautions

  • Monitor for hypoglycemia, hypokalemia, hypomagnesemia, and hypophosphatemia [21].

Dose/Administration

  • Adults:
    • Glucose 25 g (50 mL of dextrose 50%) IV bolus → 1 IU/kg IV bolus of short-acting insulin → 25 g/h glucose and 0.5-1 IU/kg/h short-acting insulin infusion [21].
  • Titrate glucose to maintain levels between 6-8 mmol/L [21].

Intravenous Lipid Emulsion

General Information

  • 20% lipid emulsion as a parenteral nutrient.
  • Expands the lipid compartment within the intravascular space, sequestering lipid-soluble drugs from tissues [1, 5].

Indications

  • Overdose by drugs with high protein binding and large volume of distribution, e.g., local anesthetics (bupivacaine), β-blockers, and calcium channel blockers [1, 5].

Dose/Administration

  • Adults: 100 mL IV bolus over 1 minute (repeat every 5 minutes, maximum 2 doses) → 18 mL/min IV infusion for 20 minutes [5].
  • Children: 1.5 mL/kg IV bolus over 1 minute (repeat every 5 minutes, maximum 2 doses) → 0.25 mL/kg/min IV infusion for 20 minutes [5].

Methylene Blue

General Information

  • Reduces methemoglobin (MetHb) to hemoglobin [5, 22].

Indications

  • Symptomatic methemoglobinemia.
  • MetHb levels >20% in asymptomatic patients.
  • Oxidizing toxins (e.g., nitrites, benzocaine, sulfonamides) [5, 22].

Precautions

  • Pulse oximetry is unreliable in methemoglobinemia.
  • May cause hemolysis in G6PD deficiency [3, 22].

Dose/Administration

  • 1-2 mg/kg slow IV injection over 5 minutes; may repeat after 30-60 minutes [5, 22].

Other Notes

  • Monitor MetHb levels frequently until a consistent decrease is observed [22].

N-acetylcysteine (NAC)

General Information

  • Prevents hepatocellular injury by restoring glutathione stores, which conjugate the toxic metabolite NAPQI [1, 3, 23].

Indications

  • Serum acetaminophen levels above toxic threshold (>4 hours after ingestion).
  • Single ingestion >150 mg/kg.
  • Evidence of liver injury [1, 3, 4, 23].

Dose/Administration

  • Oral: 140 mg/kg loading dose → 70 mg/kg every 4 hours for 17 doses [1, 3, 23].
  • IV: 150 mg/kg in 200 mL of 5% dextrose over 60 minutes → 50 mg/kg diluted in 500 mL of 5% dextrose over 4 hours → 100 mg/kg diluted in 1000 mL of 5% dextrose over 16 hours [1, 3, 23].

Other Notes

  • Oral therapy may not be well tolerated due to taste and odor [23].

Naloxone

General Information

  • Opioid antagonist, diagnostic, and therapeutic agent [1, 2, 3].

Indications

  • Opioid toxicity with respiratory and CNS depression [1, 2, 3, 5].

Precautions

  • Re-sedation may occur due to naloxone’s short half-life; monitor for at least 4 hours.
  • Withdrawal in chronic/opioid-dependent users [1, 2, 3].

Dose/Administration

  • Adults: 0.4-2 mg IV; repeat every 2-3 minutes up to a maximum of 10 mg [1, 2, 3].
  • Children: 0.01 mg/kg IV [1, 3].

Other Notes

  • Goal: Adequate respiratory rate, normal oxygen saturation on room air, improved level of consciousness [3, 5].
  • Miosis is an unreliable indicator [5].

Octreotide

General Information

  • Synthetic analogue of somatostatin [24].

Indications

  • Hypoglycemia secondary to sulfonylurea [24].

Precautions

  • Breakthrough hypoglycemia may occur [24].

Dose/Administration

  • Adults:
    • 50 µg IV bolus → 25 µg/h infusion.
    • Alternatively, 100 µg IM or SC every 6 hours [24].
  • Children: 1 µg/kg IV bolus or SC → 1 µg/kg/h IV infusion [24].

Other Notes

  • Euglycemia needs to be maintained for 12 hours off the infusion before the patient is medically cleared [24].

Physostigmine

General Information

  • Reversible acetylcholinesterase inhibitor [25].

Indications

  • Neurological anticholinergic symptoms, e.g., delirium and seizures (crosses the blood-brain barrier) [5, 25].

Precautions

  • Contraindicated in bradycardia, AV block, and bronchospasm [25].

Dose/Administration

  • Adults: 0.5-1 mg slow IV push over 5 minutes; repeat in 10-30 minutes if needed [25].
  • Children: 0.02 mg/kg IV (maximum dose of 0.5 mg) [25].

Other Notes

  • Confirm absence of conduction defects on a 12-lead ECG before administration.
  • Rapid administration may cause a cholinergic crisis; treat with atropine if this occurs [25].

Pralidoxime

General Information

  • Reactivates acetylcholinesterase inhibition [1, 3, 26].

Indications

  • Early organophosphate poisoning (<2 hours).
  • Nerve agents [1, 3, 5, 26].

Precautions

  • Rapid administration can cause laryngospasm, muscle rigidity, and transient respiratory impairment [3].

Dose/Administration

  • Adults: 1-2 g IV in 100 mL of 0.9% saline over 15-30 minutes → 500 mg/h IV infusion [3, 26].
  • Children: 25-50 mg/kg → 10-20 mg/kg/h infusion [3, 26].

Other Notes

  • Administer in the early phase before irreversible acetylcholinesterase binding occurs.
  • Adequate atropine doses should be given concurrently [1, 3, 26].

Pyridoxine (Vitamin B6)

General Information

  • Vitamin B6, essential for GABA production [3, 27].

Indications

  • Isoniazid, hydrazine, and Gyromitra poisoning.
  • Ethylene glycol poisoning (adjunct therapy) [3, 5, 27].

Dose/Administration

  • Adults:
    • For isoniazid poisoning: 1 g per gram of ingested isoniazid, given as 0.5 g/min infusion until seizures stop. If unknown, give 5 g IV empirically [3, 5, 27].
  • Children: 70 mg/kg IV, maximum 5 g [5, 27].

Other Notes

  • For ethylene glycol toxicity: 50 mg IV every 6 hours [27].

Sodium Bicarbonate

General Information

  • Hyperosmolar sodium bicarbonate injection [28].

Indications

  • Cardiotoxicity due to fast sodium channel blockade presenting as QRS widening and ventricular dysrhythmias (e.g., TCA poisoning).
  • Urine alkalinization [2, 5, 28].

Precautions

  • Monitor for hypokalemia and hypernatremia.
  • Maintain serum pH between 7.50-7.55 [28].

Dose/Administration

  • Start with 1-2 mEq/kg IV over 1-2 minutes → 0.3 mEq/kg per hour IV infusion if needed [5].
  • Repeated doses may require intubation and hyperventilation to maintain pH >7.5-7.55 [28].

Sodium Calcium Edetate (EDTA)

General Information

  • IV heavy metal chelator [29].

Indications

  • Severe lead toxicity with lead levels >70 µg/dL [29].

Precautions

  • Risk of nephrotoxicity, ECG changes, and transaminitis.
  • Hospital admission required [29].

Dose/Administration

  • Dilute 25-50 mg/kg in 500 mL of 0.9% saline or 5% dextrose; infuse over 24 hours, starting 4 hours after the first dose of dimercaprol [29].
  • In encephalopathy, continuous infusion for 5 days until stabilization [29].

Other Notes

  • Once clinically improved, switch to oral succimer if tolerated [29].

Sodium Thiosulfate

General Information

  • Assists the body in detoxifying cyanide [1, 30].

Indications

  • Cyanide poisoning [1, 5, 30].

Precautions

  • In severe cases, use with other antidotes (e.g., hydroxocobalamin) [30].

Dose/Administration

  • Adults: 50 mL of 25% solution (12.5 g; 1 ampoule) IV over 10 minutes [1, 5, 30].
  • Children: 1.65 mL/kg IV; repeat after 30 minutes if clinically indicated [30].

Succimer (DMSA)

General Information

  • Oral heavy metal chelator [31].

Indications

  • Symptomatic lead poisoning.
  • Asymptomatic lead poisoning with lead levels >60 µg/dL in adults or >45 µg/dL in children [5, 31].

Precautions

  • Reversible neutropenia, gastrointestinal upset, and liver function abnormalities [31].

Dose/Administration

  • 10 mg/kg three times a day for 1 week → two times a day for 2 weeks [31].

Other Notes

  • Monitor serum lead levels during treatment [31].

Antidotes play a crucial role in managing toxicological emergencies in the emergency department. While their use is often specific and limited, they provide life-saving interventions in cases of confirmed poisonings such as opioid overdoses, cyanide poisoning, or organophosphate exposure. However, their administration requires careful assessment of indications, contraindications, and potential adverse effects. Emergency clinicians must prioritize stabilizing airway, breathing, and circulation before considering antidote administration, except in scenarios where antidotes are critical to immediate survival. The decision to use an antidote should be guided by clinical judgment, toxicology consultation, and evidence-based guidelines. Ultimately, antidotes should be viewed as adjunctive therapies, emphasizing the principle of treating the patient comprehensively rather than focusing solely on the poison.

Author

Picture of Sarah Alzaabi

Sarah Alzaabi

Sarah Alzaabi, MD is a graduate from the United Arab Emirates University. She is currently a medical intern at Sheikh Shakhbout Medical City, Abu Dhabi, with a longstanding interest in Emergency Medicine. She is a big advocate for the FOAMed movement; and is proud to be a part of the fantastic team at iEM. She is excited to develop innovative ways to provide accessible education for anyone in need. Sarah has a particular interest in lifestyle and nutrition and spends time learning about how to educate others about succeeding in medicine while maintaining a healthy lifestyle.

Listen to the chapter

References

  1. Chacko B, Peter JV. Antidotes in Poisoning. Indian J Crit Care Med. 2019;23(Suppl 4):S241-S249. doi:10.5005/jp-journals-10071-23310
  2. Erickson TB, Thompson TM, Lu JJ. The Approach to the Patient with an Unknown Overdose. Emerg Med Clin N Am. 2007;25(2):249-81.
  3. Holstege CP, Dobmeier SG, Bechtel LK. Critical care toxicology. Emerg Med Clin North Am. 2008;26(3):715-39.
  4. Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. Principles of Managing the Acutely Poisoned or Overdosed Patient. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. eds. Goldfrank’s Toxicologic Emergencies, 11e. McGraw Hill; 2019. Accessed March 04, 2023. https://accessemergencymedicine-mhmedical-com.uaeu.idm.oclc.org/content.aspx?bookid=2569&sectionid=210267250
  5. Greene S. General Management of Poisoned Patients. Tintinalli’s Emergency Medicine. 8 ed: MC Graw Hill; 2014. p. 1207.
  6. Gei AF, Suarez VR. Poisoning in Pregnancy. In: Foley MR, Strong, Jr TH, Garite TJ. eds. Obstetric Intensive Care Manual, 5e. McGraw Hill; . Accessed March 04, 2023. https://obgyn-mhmedical-com.uaeu.idm.oclc.org/content.aspx?bookid=2379&sectionid=185993887
  7. Bailey, B. (2003), Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?. Birth Defects Research Part A: Clinical and Molecular Teratology, 67: 133-140. https://doi-org.uaeu.idm.oclc.org/10.1002/bdra.10007
  8. Long N. Atropine. Life in the Fast Lane. https://litfl.com/atropine/. Published November 3, 2020. Accessed March 23, 2023.
  9. Long N. Calcium. Life in the Fast Lane. https://litfl.com/calcium/. Published November 3, 2020. Accessed March 23, 2023.
  10. Long N. Cyproheptadine. Life in the Fast Lane. https://litfl.com/cyproheptadine/. Published November 3, 2020. Accessed March 23, 2023.
  11. Long N. Desferrioxamine. Life in the Fast Lane. https://litfl.com/desferrioxamine/. Published November 3, 2020. Accessed March 23, 2023.
  12. Long N. Digoxine Immune Fab. Life in the Fast Lane. https://litfl.com/digoxin-immune-fab/. Published November 3, 2020. Accessed March 23, 2023.
  13. Long N. Dimercarpol. Life in the Fast Lane. https://litfl.com/dimercaprol/. Published November 3, 2020. Accessed March 23, 2023.
  14. Long N. Ethanol. Life in the Fast Lane. https://litfl.com/ethanol/. Published November 3, 2020. Accessed March 23, 2023.
  15. Long N. Flumazenil. Life in the Fast Lane. https://litfl.com/flumazenil/. Published November 3, 2020. Accessed March 23, 2023.
  16. Long N. Fomepizole. Life in the Fast Lane. https://litfl.com/fomepizole/#:~:text=Fomepizole%20is%20an%20alcohol%20dehydrogenase,methanol%20and%20ethylene%20glycol%20poisoning. Published June 15, 2021. Accessed March 23, 2023.
  17. Long N. Glucagon. Life in the Fast Lane. https://litfl.com/glucagon/. Published November 3, 2020. Accessed March 24, 2023.
  18. Nickson C. Glucagon Therapy. Life in the Fast Lane. https://litfl.com/glucagon-therapy/. Published November 3, 2020. Accessed March 24, 2023.
  19. Atlantic Canada Poison Centre. https://atlanticcanadapoisoncentre.ca/glucagon-pediatric.html. Published March 2017. Accessed March 30, 2023.
  20. Long N. Hydroxocobalamin. Life in the Fast Lane. https://litfl.com/hydroxocobalamin/. Published November 3, 2020. Accessed March 24, 2023.
  21. Long N. Insulin (High dose). Life in the Fast Lane. https://litfl.com/insulin-high-dose/. Published November 3, 2020. Accessed March 24, 2023.
  22. Long N. Methylene Blue. Life in the Fast Lane. https://litfl.com/methylene-blue/. Published November 3, 2020. Accessed March 24, 2023.
  23. Long N. N-acetylcysteine. Life in the Fast Lane. https://litfl.com/n-acetylcysteine/#:~:text=Acetylcysteine%20is%20the%20most%20widely,of%20NAPQI%20(toxic%20paracetamol%20metabolite. Published November 3, 2020. Accessed March 24, 2023.
  24. Long N. Octreotide. Life in the Fast Lane. https://litfl.com/octreotide/. Published November 3, 2020. Accessed March 24, 2023.
  25. Long N. Physostigmine. Life in the Fast Lane. https://litfl.com/physostigmine/. Published November 3, 2020. Accessed March 24, 2023.
  26. Long N. Pralidoxime. Life in the Fast Lane. https://litfl.com/pralidoxime/#:~:text=This%20is%20the%20oxime%20commonly,and%20the%20OP%2FCarbamate%20involved. Published November 3, 2020. Accessed March 24, 2023.
  27. Long N. Pyridoxine. Life in the Fast Lane. https://litfl.com/pyridoxine/. Published November 3, 2020. Accessed March 24, 2023.
  28. Long N. Sodium Bicarbonate. Life in the Fast Lane. https://litfl.com/sodium-bicarbonate/. Published November 27, 2022. Accessed March 24, 2023.
  29. Long N. Sodium Calcium edetate. Life in the Fast Lane. https://litfl.com/sodium-calcium-edetate/#:~:text=Sodium%20Calcium%20Edetate%20(EDTA)%20is,3.38%20micro%20mol%2FL). Published November 3, 2020. Accessed March 24, 2023.
  30. Long N. Sodium thiosulphate. Life in the Fast Lane. https://litfl.com/sodium-thiosul phate/#:~:text=Sodium%20thiosulfate%20enhances%20the%20endogenous,hydroxocobalamin%20in%20severe%20cyanide%20toxicity.Published November 3, 2020. Accessed March 24, 2023.
  31. Long N. Succimer. Life in the Fast Lane. https://litfl.com/succimer/#:~:text=Succimer%20(DMSA)%20is%20an%20orally,2.9%20micro%20mol%2FL). Published November 3, 2020. Accessed March 24, 2023.

Reviewed and Edited By

Picture of Arif Alper Cevik, MD, FEMAT, FIFEM

Arif Alper Cevik, MD, FEMAT, FIFEM

Prof Cevik is an Emergency Medicine academician at United Arab Emirates University, interested in international emergency medicine, emergency medicine education, medical education, point of care ultrasound and trauma. He is the founder and director of the International Emergency Medicine Education Project – iem-student.org, chair of the International Federation for Emergency Medicine (IFEM) core curriculum and education committee and board member of the Asian Society for Emergency Medicine and Emirati Board of Emergency Medicine.

Fight against superdrugs

This is an essay I wrote for the Antibiotic Week celebrated at Patan Hospital back when I was a medical student. Here I portray myself as a happy bacterium that is thriving in a world where antibiotic stewardship is not followed.

Anti-Antibiotics week has been being celebrated in the bacteria world since the first beta-lactamases were invented. This year, an adolescent staphylococcus with a lot of wisdom is giving a speech.

VRSA, the vice president of Fight against Super Drugs Development (FSDD), has been actively advocating (mechanisms of antibiotic resistance) among less privileged groups of bacteria. “Triumph of hope over desperation,” said the vice-president of the FSDD club, pointing towards the antimicrobial week that humans celebrate. Then he invited a bacterium on the stage to shed some light on the glorified FSDD club.

“Hello! I am a bacterium. I belong to the staphylococcus group according to the classification done by another species here on earth. An anecdote; they consider themselves superior enough to fight against us. They are that foolish a species. Today, I’ll tell you about my daily activities and my life goals. Now, it’s a known fact that we fit in the grand scheme of things better than any other species. Well, maybe viruses are debatably our competitors in that regard, but that’s an issue I’ll consider later. My parents tell me that I am a very happy and brave bacterium, just like them. As you all know, we, staphylococci, are very social bacteria. We like in clusters and love keeping cats as pets. It’s funny how human beings think we’re catalase positive. But anyhow, Almighty didn’t make them as bright as us! They’re bad!

I love traveling. I stay in people’s homes, their dishes, food, and all the places you can imagine. I love dirty hands. I hide just under a dirty nail and say goodbye to my siblings as they go to all the places the unclean hand touches. And you’d be amazed if I tell you where people let us go without washing their hands. This one time, I was talking with my cousin Roy the streptococci under a thumb-nail, and the man under whose thumb-nail we were discussing our career option touched a tiny human being. They call them neonates, I guess. After a week,  Cousin Roy wrote to me that his career goals are being met and that he has a thriving business of causing impetigo on that small neonate’s cheeks. He is also thinking of extending his business. Chains of impetigo maybe, like chains of hotels humans came up with so that we can harbor on leftovers and unhygienic food.

If you are starting to think that humans might be actually helping us take over the world, wait till I tell you about some more kind human beings. But first I’d want to tell you about some human beings that are rude and unhelpful. They belong to no specific place and are very hard to recognize. Most of them wear this white coat and carry some long rope around their neck. They’ve invented and are using chemicals to kill us. The funny thing is, even after we had a head start in evolution; they came up with such powerful substances. But thanks to our brave ancestors who used all their wit to figure out ways to survive. (Mechanism of resistance and things like transposons etc.) that our vice president advocated at the beginning was their gift to us.

This is where the kind among these white coats-wearing people fit in the story. It would sound unbelievably funny, but they started using those chemicals so rampant that we had enough samples to bring to our labs, test them with our brightest minds and make changes in us that would render these chemicals useless. I mean, why would you use only the power you have against your strongest enemy so carelessly? They started prescribing antibiotics to people harboring our friend viruses and fungi; they started taking fewer doses of these chemicals, which helped us take samples and conduct more studies on them. As ridiculous as it may sound, they started giving them to other animals even when they weren’t sick. There are plenty of journals written by our bacteria brothers who live in pigs about inventing different approaches to render these chemicals useless. Thanks to an ample number of samples provided by the pig farmers.

Talking about researches, some are going on the human side of the battlefield too. That’s our greatest threat. But here’s the good news; we are inventing new tricks and tweaks to get by the chemicals humans use to kill us with. They are not creating more chemicals as efficiently. Once I was on the hand of this biochemist who forgot to wash his hands after touching a petri-dish; that’s my birthplace, by the way. He was in this conference where people were discussing hurdles to the development of super drugs. I was tiny then, so I couldn’t catch all of what they were speaking, but things like insufficient funding and pharmaceuticals being more interested in modifying the same drug and making it earn more for them came up repeatedly.

I would like to end with a quote I heard at that very conference. “With great power comes great responsibilities.” So, let’s remember when we come up with great ideas to get by every weapon humans have against us, we have a responsibility to share it with our offspring. Let’s rule the world!”

[cite]

Question Of The Day #58

question of the day
720 - variceal bleeding

Which of the following is the most appropriate next step in management?   

This cirrhotic patient presents to the Emergency Department with epigastric pain after an episode of hematemesis at home.  His initial vital signs are within normal limits.  While waiting in the Emergency Department, his clinical status changes.  The patient has a large volume of hematemesis with hypotension and tachycardia.  This patient is now in hemorrhagic shock from an upper gastrointestinal bleed and requires immediate volume resuscitation.  The most common cause of upper gastrointestinal bleeding is peptic ulcer disease, but this patient’s cirrhosis history and large volume of hematemesis should raise concern for an esophageal variceal bleed.  IV Pantoprazole (Choice D) is a proton pump inhibitor that helps reduce bleeding in peptic ulcers, but it does not provide benefit in esophageal varices.  Volume repletion is also a more important initial step than giving pantoprazole.  IV Ceftriaxone (Choice C) helps reduce the likelihood of infectious complications in variceal bleed patients.  This has a mortality benefit and is a recommended adjunctive treatment.  However, rapid volume resuscitation is a more important initial step.  IV crystalloid fluids, like normal saline (Choice A), are helpful in patients with hypovolemic shock (i.e., dehydration, vomiting), distributive shock (i.e., sepsis, anaphylaxis), and obstructive shock (i.e., tension pneumothorax, etc.).  Hypovolemic shock due to severe hemorrhage (hemorrhagic shock) requires blood products, not crystalloid fluids which can further dilute blood and cause coagulopathy.  Administration of packed red blood cells (Choice B) is the best next step in management in this case.

References

[cite]

Question Of The Day #57

question of the day

Which of the following is the most likely cause for this patient’s condition?  

This young female presents with dizziness, fatigue, nausea, generalized abdominal pain, hypotension, tachycardia, and a positive urine pregnancy test.  The anechoic (black) areas on the bedside ultrasound indicate free fluid (blood) in the peritoneal space.  See the image below for clarification. Yellow arrows indicates free fluids.

This patient is in a state of physiologic shock.  Shock is an emergency medical state characterized by cardiovascular or circulatory failure.  Shock prevents peripheral tissues from receiving adequate perfusion, resulting in organ dysfunction and failure.  Shock can be categorized as hypovolemic, distributive, obstructive, or cardiogenic.  The different categories of shock are defined by their underlying cause (i.e., sepsis, hemorrhage, pulmonary embolism, etc.) and their hemodynamics which sometimes overlap.  The diagnosis of shock is largely clinical and supported by the history, vital signs, and physical exam.  Additional studies, such as laboratory investigations, bedside ultrasound, and imaging tests help narrow down the type of shock, potential triggers, and guide management. 

This patient’s condition is caused by a presumed ruptured ectopic pregnancy and intraperitoneal bleeding.  This is considered hypovolemic/hemorrhagic shock (Choice A). The other types of shock in Choices B, C, and D are less likely given the clinical and diagnostic information in the case.  The chart below details the categories of shock, each category’s hemodynamics, potential causes, and treatments.  

 

References

[cite]

Question Of The Day #56

question of the day

Which of the following is the most likely cause of this patient’s condition?

This trauma patient arrives with hypotension, tachycardia, absent unilateral lung sounds, and distended neck veins. This should raise high concern for tension pneumothorax, which is a type of obstructive shock (Choice C). This diagnosis should be made clinically without X-ray imaging. Bedside ultrasound can assist in making the diagnosis by looking for bilateral lung sliding, if available. Treatment of tension pneumothorax should be prompt and includes needle decompression followed by tube thoracostomy. Other types of shock outlined in Choices A, B, and D do not fit the clinical scenario with information that is given.

Recall that shock is an emergency medical state characterized by cardiovascular or circulatory failure. Shock prevents peripheral tissues from receiving adequate perfusion, resulting in organ dysfunction and failure. Shock can be categorized as hypovolemic, distributive, obstructive, or cardiogenic. The different categories of shock are defined by their underlying cause (i.e., sepsis, hemorrhage, pulmonary embolism, etc.) and their hemodynamics which sometimes overlap. The diagnosis of shock is largely clinical and supported by the history, vital signs, and physical exam. Additional studies, such as laboratory investigations, bedside ultrasound, and imaging tests help narrow down the type of shock, potential triggers, and guide management. The chart below details the categories of shock, each category’s hemodynamics, potential causes, and treatments.

 

References

[cite]

Question Of The Day #55

question of the day
738.2 - STEMI
Which of the following is the most likely cause for this patient’s condition?  

This patient presents with chest pressure at rest and an anterior ST segment elevation myocardial infraction (STEMI) seen on 12-lead EKG.  This patient should be given aspirin, IV fluids to increase the preload status, and receive immediate coronary reperfusion therapy.  This patient’s hypotension is likely due to infarction of the left ventricle causing poor cardiac output (Choice D).  This is known as cardiogenic shock.  The patient has been vomiting, but the acute onset of symptoms and STEMI on EKG make poor cardiac output (Choice D) more likely than hypovolemia (Choice A) as the cause for the patient’s condition.  Systemic infection (Choice B) and pulmonary embolism (Choice C) are also less likely given the clinical information in the case and the STEMI on EKG.  The best answer is Choice D.  Please see the chart below for further detailing of the different types of shock.   

References

[cite]

Question Of The Day #54

question of the day
Which of the following is the most likely cause for this patient’s condition?

This patient sustained significant blunt trauma to the chest, presents to the Emergency Department with hypotension, tachycardia, a large chest ecchymosis, and palpable sternal crepitus.  The ultrasound image provided shows a subxiphoid view of the heart with a large pericardial effusion.  In the setting of trauma, this should be assumed to be a hemopericardium.  This patient has cardiac tamponade, which is considered a type of obstructive shock (Choice C).  Treatment includes IV hydration to increase preload, bedside pericardiocentesis, and ultimately, a surgical cardiac window performed by cardiothoracic surgery.  The other shock types (Choices A, B, D) do not describe this patient’s presentation.  Please see the chart below for further description of the different shock types and therapies.

 

References

[cite]